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KURZFASSUNG 
Einer einzelnen microRNA ist es möglich über die Bindung an den 3’ untranslatierten 
Bereich hunderte mRNAs zu regulieren. Deswegen sind sie maßgeblich an der 
Ausbildung von spezifischen Expressionsmustern beteiligt, die die 
Entwicklungsprogramme festlegen und Krankheiten verursachen. Von einigen 
microRNAs ist bekannt, dass sie in Krebs dereguliert sind, was eine wichtige Rolle 
bei Entstehung und Entwicklung von Tumoren nahelegt. Zu dieser Gruppe von 
microRNAs gehört auch microRNA-21(miR-21); sie agiert als sogenanntes oncomiR 
und ist in einer Vielzahl verschiedener soliden Tumoren überexpremiert. Bekannte 
Substrate von miR-21 sind Tumorsupressoren wie z.B. Programmed Cell Death4 
(PDCD4), Phosphatase and tensin homolog (PTEN), Sprouty1 (Spry1) und Sprouty2 
(Spry2). 
In dieser Studie haben wir die miR-21 Expression im Lungenkrebs untersucht und 
herausgefunden, dass in kultivierten Lungenkrebszelllinien die Levels von miR-21 
kaum von jenen in normalen Lungenfibroblasten abweichen. Zusätzlich war die 
Korrelation miR-21 Expression und Proteinlevel von PDCD4, PTEN, Spry1 und Spry2 
insignifikant. Auch die Proliferationsrate der Zelllinien stand in keinem 
Zusammenhang zu den gemessenen miR-21 Levels. Ebenso insignifikant war der 
Unterschied von miR-21 Expression in Adenokarzinomen und Plattenzellkarzinomen.  
Auf der Suche nach endogenen Verursachern der miR-21 Expression in Tumoren 
fanden wir, dass Zelllinien mit einer Mutation im EGFR Gen annähernd dieselben 
miR-21 Levels wie Zelllinien, die die Wildtypversion dieses Gens tragen, zeigen.  
Zelllinien, die eine onkogene Mutation im Ras Gen haben im Mittel zwar geringfügig 
höhere miR-21 Werte, aber die Abweichung war nicht signifikant. Da auch eine 
ektopische Expression von onkogen mutierten H-, K- und N-Ras zu keiner 
Veränderung der miR-21 Expression führte, liegt nahe dass Ras Mutationen keinen 
Einfluss auf die Regulation von miR-21 Expression haben.  
Während Überexpression von Spry1 keinen Effekt auf miR-21 hat, führen hohe 
Levels von Spry2 zu einer signifikanten Reduktion der miR-21 Expression. 
Möglicherweise gibt es eine Rückkopplungsschleife zwischen miR-21 und Spry2.  
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Im zweiten Teil der Studie wurden verschiedene Strategien zur Modulierung der miR-
21 Expression verglichen. Überexpression von verkürzten primiR 21 RNA durch ein 
virales System zeigte in einer der getesteten Zelllinien die gewünschte Wirkung. Um 
miR-21 zu inhibieren wurden verschiedene Ansätze ausprobiert. Während die 
adenovirale Produktion von antisense Oligonukleotiden und von siRNA durch einen 
RNA Polymerase III Promotor gegen primiR 21 die miR-21 Levels und die 
Expression der untersuchten Substrate nicht nennenswert veränderte, zeigen Zellen 
der Zelllinie U373, die mit dem sponge eraser Konstrukt infiziert wurden, im Vergleich 
zu Kontrollzellen signifikant reduzierte miR-21 Expression. Diese Daten führen zu der 
Annahme, dass die Produktion von sponge eraser Konstrukten die beste Strategie ist 
um mit der miR-21 Funktion in Tumor- Zelllinien zu interferieren.   
IV 
 
ABSTRACT 
MicroRNAs can regulate hundreds of mRNA by binding at the 3’ untranslated regions 
and are therefore involved in regulation of gene expression during development and 
disease. Some microRNAs are known to be deregulated in cancer and play an 
important role in governing initiation and progression of tumors. MicroRNA-21(miR-
21) is one of the microRNA known to act as an oncomiR. It is overexpressed in 
diverse solid tumors. Identified targets of miR-21 are tumor suppressors like 
Programmed Cell Death4 (PDCD4), Phosphatase and tensin homolog (PTEN), 
Sprouty1 (Spry1) and Sprouty2 (Spry2). 
In this study we investigated miR-21 expression in non small cell lung cancer 
(NSCLC) derived cell lines and discovered that in cultured NSCLC derived cell lines 
miR-21 expression is comparable to the levels in normal lung fibroblasts. MiR-21 
levels failed to show significant inverse correlation to the protein expression of 
PDCD4, PTEN, Spry1 and Spry2. Furthermore we were unable to detect a 
correlation between expressions of miR-21and proliferation rate. MiR-21 expression 
in cell lines derived from adenocarcinoma and squamous cell carcinoma were 
analyzed but no connection between histological type of lung cancer and miR-21 
levels can be found. 
Cell lines with a mutation in EGFR gene have almost the same levels of miR-21 
compared to cell lines harboring the wild type gene.  
Although cell lines harboring an oncogenic mutation in the Ras gene show on 
average higher levels, overexpression of oncogenic H-, K- and N-Ras does not lead 
to an alteration of miR-21 expression. These results indicate that Ras has no 
influence on the regulation of miR-21 expression.  
While overexpression of Spry1 has no effect on miR-21 levels, high levels of Spry2 
lead to significant reduced miR-21 expression. Maybe there is a feedback loop 
between miR-21 and Spry2.  
In the second part of the study we compared different strategies to modulated miR-21 
levels. Overexpressing of a shortened primiR 21 RNA by a viral system worked at 
least in one of the chosen cell lines. In order to achieve inhibition of miR-21 we tested 
different strategies. While adenoviral production of antisense oligonucleotides by an 
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RNA polymerase III promoter as well as expression of an siRNA against primiR 21 
failed to reduce miR-21 levels and increase substrate levels, cells which are infected 
with a sponge eraser, show significant reduced miR-21 levels in U373 cell line 
compared to control cells. These data indicate that production of sponge eraser 
constructs is the most powerful way to interfere with miR-21 function in tumor-derived 
cell lines.  
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1 INTRODUCTION 
1.1 Cancer 
Tumorigenesis is a multistep process, whereby cells are subject to various 
alterations, which are the result of an accumulation of genetic and epigenetic 
changes (1) (2). Alterations in three types of genes are involved in tumorigenesis: 
oncogenes, tumor suppressor genes and stability genes. Oncogenes are altered by 
mutations which lead to an activate gain of function, while mutations in tumor 
suppressor genes result in reduce of activity of these gene products. Stability genes 
are involved in DNA damage repair (e.g. miss match repair, nucleotide excision 
repair and base excision repair genes) and therefore these genes reduce mutations 
in other genes. When stability genes are altered, mutation rate in other genes 
increases (3). 
In tissue it is necessary that cell proliferation, arrest and cell death are in equilibrium. 
On that account cell growth is regulated by several signaling pathways. Six essential 
alterations involved in the transformation from normal to malignant cells are shown in 
Figure 1. These so called hallmarks of cancer are sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, inducing angiogenesis, enabling 
replicative immortality and activating invasion and metastasis (1). 
 
 
 
Figure 1: Acquired Capabilities of Cancer (1) 
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Cancer cells do not respond to growth promoting or growth suppressing signals, like 
other normal cells do. The independence of these factors can be acquired for 
example from alterations of receptors or changes in components of downstream 
signaling pathways like Ras. 
Programmed cell death is a natural limitation for tumor development. Through 
apoptosis, cells with DNA damage can be removed and it is an important program for 
growth homeostasis. In tumor tissue, antiapoptopic factors (e.g. Bcl-2) or survival 
signals (e.g. Igf 1/2) are increased, while proapoptotic factors are downregulated. 
Another feature which is unique for tumor cells is enabling replicative immortality. 
Normal cells can only pass a limited number of cell doublings before they undergo 
senescence or crisis. Cancer cells get immortalized, so that they have the potential 
for unlimited replication, which can be achieved e.g. by activation of telomerase.  
Additionally, tumor tissue has to induce angiogenesis because it is essential for cells 
to get nutrients and oxygen. The so called angiogenic switch leads to new vessels, 
which help to provide the tumor. Proangiogenic factors are signal proteins which are 
increased in malignant cells. 
Another hallmark of cancer is activation of invasion and metastasis. Patients die 
much more often due to metastasis, than on the primary tumor. Formation of the 
secondary tumors results from cells which leave the primary tumor and travel in blood 
or lymphatic vessels to other parts of the body where they begin to grow and form a 
new tumor. Invasion and metastasis is an effect of increased migratory and invasive 
abilities. Alterations of gene expression, including modification of signals of some 
receptor tyrosine kinases and changed binding specify of cadherins and integrins are 
essential for activating metastasis and invasion (4) (5). 
Additionally to these 6 hallmarks of cancer, microenvironment plays an important role 
in cancer development. Tumor cells do not grow isolated; they are in contact with 
their environment. Tumor stroma, the microenvironment of malignant cells 
communicates with the tumor via paracrine signals and leads to cancer initiation and 
growth. Tumor cells are in touch with the components of the stromal parts, e.g. 
endothelial cells, pericytes, fibroblasts and immune cells (6). 
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1.1.1 Lung cancer: 
In 2008 lung cancer was the most frequent diagnosed cancer worldwide. 18% of all 
cancer related deaths were arisen from lung cancer, which makes it to the leading 
cause of cancer deaths (7). 
Lung cancer is strongly associated with tobacco smoking. The main risk factor for 
lung cancer is smoking. Cancerogens in the smoke lead to an accumulation of 
genetic changes. Additionally, environment factors (e.g. exposure to cancerogens 
like asbestos, arsenic and radon) and genetic factors are involved in the 
development of lung cancer (8) (9). 
Histological there are two subtypes of lung cancer: 
Small cell lung cancer (SCLC) counts for 20% of all lung cancer cases and consists 
of small and round cells, which grow very aggressive with distant metastasis. This 
form of lung cancer is strongly associated with smoking; 98% of all cases have a 
history of cancer (10). Several genetic and epigenetic alterations are representative 
for SCLC. For example loss of heterozygosity of Chromosome 3p and Fragile 
histidine triade (FHIT) are common and also inactivation of Retinoblastoma (Rb) and 
p53 is very frequent in SCLC (8). 
 
Non small cell lung cancer (NSCLC) represents about 80% of all lung cancers and 
can be categorized in non squamous carcinomas, including adenocarcinomas, large 
cell carcinomas and other types of cells and squamous cell (epidermoid) carcinomas. 
The most common form of NSCLC is adenocarcinomas, which are also the most 
frequent lung cancer in non-smokers. Squamous cell carcinoma counts for 20% of all 
lung cancer cases and is the subtype with the best prognosis (9) (10). 
Activation of oncogenic K-Ras occurs to 20% in NSCLC, while in SCLC it’s very rare. 
Other genes which are overexpressed in lung cancer are e.g. ERBB1 (which 
encodes for EGFR), Cyclin D1 and B1, Bcl-2 and the myc proteins (8). 
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1.2 MicroRNA 
MicroRNAs (miRNAs) are 19-24 nucleotides (nt) long, non coding RNAs, which are 
involved in the regulation of gene expression by targeting messenger RNAs (mRNAs) 
posttranscriptional. The first miRNA was discovered 1993 in C. elegans and was 
called lin-4. Since that time thousands more were explored. MiRNAs are involved in 
nearly every cellular process, including development, differentiation, cell proliferation 
and apoptosis. About 30% of all protein coding genes in humans are regulated by 
miRNAs, wherein a single miRNA can regulate up to 200 different targets. Because 
of these facts, it is hardly surprising that changes in the expression pattern of 
miRNAs leads to human pathologies, e.g. cancer (11) (12). 
1.2.1 Biogenesis and mechanisms of post-transcriptional 
regulation of microRNAs 
Processing of miRNA starts with a primary transcript, termed primiR, which is 100 
base pairs (bp) to several kilo bp long. PrimiR is a transcript from independent 
miRNA genes and is available as a hairpin structure, containing a polyA tail and a 5’ 
cap (11) (13). 
PrimiRs get cleaved by a nuclear RNase III enzyme, called Drosha and DiGeorge 
syndrome critical region gene 8 (DGCR8) into a 60-70 nt long precursor miRNA 
(termed premiR) (11). Cleavage by Drosha is not indispensable: PremiR can also be 
a result from splicing, which is called mitron (13). Afterwards premiR is transported 
into the cytoplasm by Exportin 5, a nuclear export protein (11). 
Maturation takes place in cytoplasm by Dicer, a cytoplasmic RNase III and its binding 
partner human immunodeficiency virus transactivating response RNA-binding protein 
(TRBP), which results in a 19-29 nt mature miRNA duplex. One of these strands is 
loaded to ribonucleoprotein complexes (microRNPs) or miRNA-induced silencing 
complexes (miRISCs), the other is removed for degradation. Important components 
of the microRNPs are the Argonaute protein family (AGO). In mammalians 4 AGO 
proteins can be found, which are all involved in miRNA-mediated translational 
repression (12). Figure 2 shows a schematic illustration of the biogenesis of miRNA. 
  
  
Figure 2: Biogenesis of microRNAs 
 
MiRNAs find their substrates by sequences which are complementary to the 
nucleotide 2 to 8, the so called seed region. The target regio
the 3’untranslated regions (UTR) of target mRNAs, but sometimes there are binding 
sites for miRNAs at the 5’UTR or in coding regions too 
MiRNA base pairing with target mRNA influences 
specific mRNA. An important factor in this connection is the base pairing between 
miRNA and mRNA: nearly perfect complementary results in mRNA degradation by 
endonucleolytic cleavage of the target mRNA at the miRNA binding
(12) 
n can mainly be found at 
(12). 
stability and translation of this 
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 site by AGO 
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proteins. After cleavage RISC gets released and can bind to another mRNA. Thereby 
one miRNA can regulate several mRNAs. Imperfect base pairing leads to 
translational silencing, blocking of target mRNAs and mRNA destabilization (11). 
Silenced mRNA moves to cytoplasmatic processing bodies, the so called p-bodies, 
where they get stored. Finally degradation of these mRNA takes place in the p-
bodies by proteins like Dcp1/ Dcp2 (mRNA decapping enzymes) and Xrn 1 
(exonuclease) (14) (15). 
1.2.2 MicroRNAs and cancer 
50% of human miRNAs are located at regions of the genome which are associated 
with cancer, e.g. on fragile sites. This finding indicates that miRNAs play an important 
role in tumorigenesis. Characterization of miRNA expression profiles shows that the 
expression correlates with the development of cancer. MiRNAs can function either as 
tumor suppressors or as oncogenes (“oncomiRs”) (16) (17). 
The reduction or deletion of miRNAs, which act as a tumor suppressor leads to the 
development of tumors and results in uncontrolled expression of target oncogenes. 
Consequences of this are increased proliferation, invasion and angiogenesis and 
reduced cell death. If miRNAs have an oncogenic role, they are called oncomiRs. 
OncomiRs are overexpressed in cancer and so the functions of target tumor 
suppressors are inhibited (18). 
Examples for miRNAs which are involved in cancer development and progression are 
shown in Table 1 and Table 2.  
The first connection between aberrant miRNA expression and cancer was shown in 
B-cell chronic lymphocytic leukemia (CLL). Deletion or downregulation of miR-15a 
and miR-16-1 were found in 68% of all CLL cases (19). These miRNAs act as tumor 
suppressor genes and their loss or downregulation results in changed expression of 
oncogenes. For example miR-15a and miR-16-1 negative regulate Bcl-2 expression, 
which is known as an anti-apoptotic gene (20).  
 Table 1: Overview of common upregulated miRNAs in cancer (oncomiRs) 
Table 2: Overview of common miRNAs, which act as tumor suppressors 
MiRNAs, which are often aberrant expressed in cancers, are miR
and miR-21. 
-143, miR
9 
 
(21) 
 
(21) 
-145, let-7 
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MiRNAs, which are often downregulated in tumors, are miR-143 and miR-145. 
Interestingly in colorectal tumors only the mature form was found to be 
downregulated compared to normal tissue. The precursor transcript was found to be 
expressed similar in normal and tumor tissue, indicating that processing of miR-143 
and miR-145 is disrupted in cancer (22). 
MiRNAs which are encoded by the let-7 family often regulate oncogenes, e.g. Ras, 
and therefore are involved in cell proliferation and differentiation. Decreased 
expression of these miRNAs is associated with lung cancer (23). 
MiR-21 is an example for miRNAs, which are overexpressed in several types of 
cancer.  
 
1.2.3 Modulation of microRNAs in cancer 
MiRNAs show an aberrant expression in cancer, thus they are a target anticancer 
drugs. With one therapeutic there is the possibility to target multiple genes. For this 
reason several strategies for modulation of miRNAs were explored (24) (25). 
The first strategy to inhibit miRNA was antisense oligonucleotides (as 
oligonucleotides), which anneal to the mature miRNA strand and lead to degradation 
or duplex formation. This results in inactivation of the function of miRNAs and a 
derepression of their targets. Oligonucleotides, which were induced in D. 
melanogaster inhibit successful their target miRNA but in C. elegans this strategy 
fails. The reason therefore is that chemical structure modulations were necessary to 
increase stability, specify and binding affinity to the target miRNA. One of these 
modulations is the introduction of 2’-O-methyl groups which leads to a higher binding 
affinity to RNA. Further experiments show that such oligonucleotides are effective in 
several human cancer cell lines (Figure 3B) (24) (21). 
MiRNA sponges carry multiple binding sites in tandem to a target miRNA. Sponges 
contend with the miRNA targets for binding with the mature miRNA. Sponge activity 
is under control of strong promoters like Human cytomegalovirus (CMV) and U6 and 
often carries a reporter gene like green fluorescence protein (GFP) or luciferase. 
Sponges which are totally complementary to the seed sequence show moderate 
efficiency of inhibiting miRNA, while base mispairing at position 9-12 leads to more 
efficiency by a more stable interaction with target miRNA (Figure 3D) (24) (25) (26). 
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MiR-masking antisense oligonucleotides technology (miR-mask) are single strand 
oligonucleotides, modified by a 2’-O-methyl-group and show fully complementary to 
the binding sites of miRNA at the 3’ UTR of the target genes. MiR-masks cover up 
this binding sites and lead to the suppression of miRNA activity (Figure 3C) (24). 
Another strategy to inhibit miRNA is with RNA interference (RNAi) methods by small 
interfering RNA (siRNAs). This strategy was formerly thought to be useless because 
processing of miRNA take place in the nucleus whereas siRNAs are mainly active in 
the cytoplasm. But if siRNA is designed to target the promoter of miRNA gene as well 
as the sequence of the primiR, RNAi is a successful tool to inhibit miRNAs. MiRNA 
processing was reduced by expressing hairpin siRNA constructs, which are 
complementary to the precursors of miRNAs, resulting in a decrease of active mature 
miRNA (Figure 3A) (25).  
Not all miRNAs act as oncomiRs, some of them show activity as tumor suppressors 
and therefore approaches for targeting miRNA by overexpressing them were done.  
Synthetic oligonucleotides were introduced into the cells. These so called miRNA 
mimics are identical to endogenous miRNAs and are small double stranded and 
chemical modified oligonucleotides. Often longer mimics which include sequences of 
precursors of miRNA (premiR or primiR) which should be overexpressed, are used. 
MiRNA mimics are shown to induce cell death and decrease cell proliferation (Figure 
3E) (24) (27). 
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Figure 3: Modulation of miRNAs in cancer; A: Inhibition of miRNA by complementary 
siRNAs to miRNA precursors; B: As oligonucleotides with complementary to mature 
miRNA; C: miR-mask are complementary to the 3’UTR by covering up the binding 
site for miRNAs; D: miRNA sponges carried multiple tandem sequences and 
compete with targets of miRNA; E: miRNA mimics are identical with endogenous 
miRNAs and were introduced into the cell (adapted from Garzon et al. (24)). 
 
1.2.4 MicroRNA-21 
MiR-21 plays a role in cancer development und diagnoses and is downregulated in 
cardiovascular diseases (28) (29).  
MiR-21 is a highly conserved miRNA among species. The miR-21 gene is located at 
Chromosome 17, on the 10th intron of the Transmembrane protein 49 gene 
(TMEM49). Expression of the miRNA is under control of an own promoter and not 
driven by the promoter of the TMEM49 gene (28) (29).  
The primary transcript, the 3433 nt long primiR 21 is processed to the 72 nt long 
premiR21. This precursor gets cleaved to a 22 nt mature miR-21 (28) (29). 
siRNA 
 A
B
D
C
E
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Overexpression of miR-21 was found in many different tumor types, e.g. glioblastoma 
(30), breast (31) (32), colorectal (33) (34), liver (35), head and neck (36), esophageal 
(37), and lung cancer (38) (39). According to the function of miR-21 as an oncomiR, 
most targets are genes which act as tumor suppressors. An overview of the activity of 
miR-21 in cancer cells is depicted in Figure 4. 
The regulation of expression of miR-21 is very complex and multiple transcription 
factors like activator protein1 (AP-1) (40), Transforming growth factor (TGF)-β1 (41) 
and signal transducer and activator of transcription 3 (STAT3) (42) are important for 
regulation of transcription. An auto regulatory loop between AP-1, miR-21 and 
Programmed cell death 4 (PDCD4) is known: After induction of miR-21 expression by 
AP-1 the PDCD4 levels, a target of miR-21 decrease. PDCD4 is important for 
stimulation of AP-1 in response to Ras (43).  
 
 
Figure 4: miR-21 activity in cancer (28) 
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The best studied target of miR-21 is PDCD4 (44) (45), which acts as tumor and 
metastasis suppressor and is upregulated during apoptosis.  
Another gene which is negatively regulated by miR-21 is Phosphatase and tensin 
homolog (PTEN) (35), which inhibits the phosphoinositide-3-kinase (PI3K) pathway. 
This pathway is often activated in many malignant cells and is involved in the 
regulation of cell survival. PTEN is repressed by miR-21, which leads to increased 
cell migration and metastasis.  
Sprouty1 (Spry1) (46) and Sprouty2 (Spry2) (47) were identified as target of miR-21. 
Both are regulators of the receptor tyrosine kinase (RTK) signaling and act as 
repressors of mitogen-activated protein kinase (MAPK) pathway. Spry2 is also known 
to induce the upregulation of PTEN (48).  
15 
 
 
Table 3: Overview of miR-21 targets (29) 
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1.3 Sprouty proteins 
1.3.1 Structure of Sprouty proteins 
Sprouty (Spry) was first discovered in D. melanogaster, it is involved in development 
of the trachea by antagonizing Fibroblast Growth factor (FGF) signaling (49). 
Subsequent, Spry proteins were shown to inhibit RTK signaling. Further analyses 
show that Spry had homolog proteins in e.g. mouse (50), chicken (51), zebrafish (52), 
frog (53) and humans (54). In mammals there are four different Spry proteins known, 
named Spry1-4 (55). dSpry contains 501 amino acids and has a molecular mass of 
63kDa, while hSpry (human Spry) are smaller and show a molecular mass of 32-
35kDa (56) (57). 
The whole Spry family is characterized by highly conserved cystein rich domain at 
the C-terminus and shows divergence in the N-terminus of the protein (58) (59). In 
Figure 5 schematic illustration of the structure of Spry proteins is shown. The cystein-
rich region (termed Spry Domain) harbors a highly conserved Raf-1 binding domain 
(RBD) (57). This domain is necessary for the localization of Spry at the plasma 
membrane by binding to phosphatidylinositol-4,5-bisphosphate (56) (58). 
The N-terminus shows more variance between the different Spry proteins, but 
includes a short motif, with a central tyrosine residue (Y) (57) and a serine rich 
domain (55). Phosphorylation of tyrosine is for each Spry protein specific and the 
function as inhibitor depends on it (56).  
 
Figure 5: Structure of Spry proteins. Tyrosine residue is shown in yellow and the 
serine rich region in green. Additionally Raf1- binding domain is labeled red, while 
Spry domain is represented in blue (57). 
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1.3.2 Expression of Sprouty proteins 
Spry1, 2 and 4 are expressed widespread over adult and embryonic tissue, while 
Spry3 seems to be restricted to adult brain and testes.  
Expression of Spry depends on tissue specific factors and differs in different cell 
types. Spry expression is induced by growth factor stimuli such as Epidermal Growth 
Factor (EGF), FGF, Vascular Endothelial Growth Factor (VEGF), Platelet-Derived 
Growth Factor (PDGF), Nerve Growth Factor (NGF), Hepatocyte Growth Factor 
(HGF) and other factors like insulin, stem cell factor/kit ligand (SCF), Glial cell line-
Derived Neurotrophic Factor (GDNF), Brain-Derived Neurotrophic Factor (BDNF) and 
T-cell receptor activation. Spry expression is dependent on RTK signaling, which 
indicates that Spry is included into a negative feedback loop of signaling (60). 
After the induction of expression of Spry by several stimuli, Spry translocates to the 
plasma membrane, where MAPK pathway modulation takes place. There are 
different mechanisms, how Spry modulate RTK signals. Figure 6 depicts action of 
Spry under FGF, VEGF (Figure 6C) and EGF-mediated signaling (Figure 6D) (58) 
(60).  
1.3.3 Function of Sprouty proteins 
Spry are modulators of RTK signaling by interacting with extracellular signal-
regulated kinase (Erk)/ MAPK pathway.  
Figure 6A shows Ras/Raf/MAPK pathway and PLC-γ pathway in the absence of 
Spry. Signal transduction is activated by the binding of the growth factor to the RTK, 
which leads to autophosphorylation of the target receptor. Thereby adaptor proteins 
like Grb2 can bind by Src-homolog2 (SH2) or phosphotyrosine-binding (PTB) 
domain. Accordingly Sos bind to Grb2 and activate Ras- GTPase through the change 
of GDP to GTP. Ras, which have bound GTP activate Raf (MAPK kinase kinase) by 
phosphorylation, which activates MEK (MAPK kinase). MEK in turn activates ERK1/2 
(MAPK), which results in phosphorylation of target proteins. The point where Spry 
interact with the pathway varied (58).  
In phosphatidylinositol-specific phospholipase C (PLC)-γ pathway, the downstream 
effector PLC-δ (a Raf kinase) is able to activate MAPK in a Ras independent way by 
phosphorylating and activating Raf. 
 If c-Cbl ubiquitin ligase is present, it can bind to the phosphorylated receptor, which 
results in ubiquitination and later on in degradation of RTK 
In case of FGF, Spry1 or Spry
activation of RTK. This generates binding sites molec
PTB domains, such as Grb2. Binding of Spry to Grb2 leads to in inhibition of 
Ras/Raf/MAPK pathway upstream of Ras 
proteins are able to act as homo
results in direct binding of Raf on the RBM domain of Spry 4, which prevents Raf 
from phosphorylation through PLC
homologues harboring a RBM, it is supposed that all members of the 
family are able to inhibit MAPK pathway in this 
 
Figure 6: Modulation of RTK signaling by Spry proteins; 
(green) and PLC-γ pathway (yellow) when no Spry is av
resulting degradation of growth factor receptor by c
Spry when either VEGF (yellow) or FGF (green) bind to the receptor; 
EGFR signaling through Spry (adapted from 
(Figure 6
2 gets phosphorylated at its tyrosine residue after the 
ules, which harboring SH2 or 
(61). FGF stimulation shows that Spry 
- and heterooligomers (62). RTK stimulation of VEGF 
-δ kinase (63). Based on the fact, that all Spry 
way (Figure 6C) (58)
A: Ras/Raf/MAPK pathway 
ailable; B: Ubiquitination and 
-Cbl; C: Repression of RTK by 
Christofori et al.(58)) 
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In contrast to inhibition of MAPK pathway through Spry, EGF mediated-signaling is 
enhanced by Spry2. EGF Receptor (EGFR) is normally degraded by ubiquitination 
through c-Cbl. In presence of Spry2, c-Cbl prefers to bind to it than to EGFR. 
Interaction of Spry2 with c-Cbl, CIN85 an endocytic adapter, which is needed for 
clustering of c-Cbl and Hepatocyte growth factor-regulated tyrosine substrate (Hrs) 
which is involved in EGFRs trafficking to late endosomes, leads to sustained EGF-
mediated signaling as well as to multiubiquitination and degradation of Spry2 (Figure 
6D) (64) (65) (66).  
Spry proteins are also known to interact with PLC-γ and therefore leads to decreased 
PLC-γ signaling (67).  
1.3.4 Sprouty proteins in cancer 
In cancer RTK signaling is often activated due to aberrant expression of their 
modifiers. Aberrant expression of Spry proteins, such a modifier of RTK signaling, is 
associated with the malignant phenotype (57) (68) (69) (70). Downregulation of Spry2 
was shown in breast (71), prostate (72), liver (73), lung cancer (74) and melanomas 
(75). Results of Spry2 expression in colorectal cancer are not that clear: Holgren et 
al. shows that Spry2 expression is upregulated in colonic adenocarcinomas (76), 
while Feng et al. detected a decrease of Spry2 expression in colon cancer, especially 
in advanced stage tumors (77). 
The first evidence that Spry proteins act as tumor suppressor was found in an 
osteosarcoma cell line, in which overexpression of Spry2 inhibit tumor growth and 
metastasis (78). Later on it was shown that overexpression of Spry1 in prostate 
cancer cell lines leads to decrease in cell proliferation and inhibits colony formation 
(79). In addition, inhibition of anchorage-independent growth and migration can be 
observed (80).  
In prostate cancer overexpression of Spry1 in cell lines shows a tumor suppressing 
effect by inhibiting cell proliferation and inducing apoptosis (79). Spry4 shows no 
influence on proliferation but inhibits cell migration (81).  
Increased expression of Spry2 in NSCLC leads to inhibition of cell proliferation in K-
Ras mutated cell lines and tumor formation in vivo (74).  
Studies with a dominant negative Spry2 form, which is mutated at the tyrosine 
residue show larger tumors compared to the control in breast (71) and increased 
phosphorylated Erk levels and neoplastic transformation in liver cancer (82). 
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Spry is involved in other cellular functions, which are involved in development of 
cancer. In Spry4 knock down mice the effect of Spry4 on angiogenesis was 
investigated and showed that downregulation of Spry4 results in increased growth 
and vascularization (83).  
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2 AIM OF THE STUDY 
Cancer is the result of an accumulation of genetic and epigenetic changes, which 
results in changes in cellular features like increased proliferation and migration as 
well as inhibition of apoptosis (1) (2). Altered expression and functions of oncogenes 
and tumor suppressor genes involved in cancerogenesis are not only results of 
changes in the coding sequences but may also result from altered functions of small 
non coding RNAs. Especially miRNAs were found deregulated in tumors and seem to 
play an important role in initialization and progression of cancer (16) (17). The most 
frequently overexpressed endogenous miRNA in solid tumors is miR-21 (38). MiR-21 
acts as an oncomiR and represses translation by binding to the 3’UTR of the mRNA 
of tumor suppressors, such as PTEN, Spry and PDCD4 (29). Four different Spry 
proteins exist in mammalians (Spry1, 2, 3 and 4), whereby only Spry1 and Spry2 are 
confirmed to be targets of miR-21. Spry proteins regulates MAPK pathway mainly by 
repressing RTK signaling, with exception of EGFR-mediated signaling where Spry 
shows an enhancing effect (56) (58). 
MiR-21 was found to be upregulated in lung cancer tissue (38) (39). In this study it 
should be determined if the same observation which was made in tumor can also be 
found in NSCLC derived cell lines compared to normal lung fibroblasts (WI-38). 
Therefore cell lines harboring mutations in Ras or EGFR gene as well as cell lines 
without mutations are used and endogenous levels of miR-21 in different NSCLC cell 
lines will be detected by Northern blotting to explore if miR-21 is overexpressed in 
cell lines too. Additionally the endogenous expression of target proteins of miR-21 
(PDCD4, PTEN, Spry1 and Spry2) will be detected by Western blotting. Protein 
levels will be compared with miR-21 expression. Furthermore expression of miR-21 
in cell lines derived from adenocarcinomas will be compared to levels in squamous 
cell carcinoma cell lines.  
 
Due to the fact that miR-21 expression is regulated by a feedback loop with its target 
PDCD4 (43), we will explore if there is a feedback loop between miR-21 and Spry1 or 
Spry2.  
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Within this study methods for overexpression and inhibition of miR-21 by viral vectors 
should be establish. For overexpression a vector which express primiR 21 will be 
used. To figure out which is the best strategy to inhibit miR-21, three different 
methods will be used: The plasmid pAdlox sponge 21 containing a CMV promoter, a 
luciferase reporter gene and the antisense sequence against miR-21 in tandem is 
already available in the labor. Construction of pAdlox oligo eraser 21(plasmid 
containing an U6 promoter and one antisense sequence for miR-21) and pAdlox 
simiR 21 (plasmid producing siRNA against primiR 21) will be constructed.  
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3 MATERIAL AND METHODS 
3.1 Cell culture 
3.1.1 Used cell lines 
All used cell lines are derived from human origin and are split in an adequate ratio 
with Trypsin/ EDTA (T/E). All used cell lines are listed in Table 4. 
Cell line 
Source / Alias 
Origin 
Site 
Type Medium Characteristics 
U373 
ATCC-HTB17 
Brain Glioblastoma DMEM Split ratio: 1:9 
WI 38 
ATCC-CCL75 
Lung Diploid human 
fibroblasts, 
derived from 
normal embryonic 
lung tissue 
DMEM Split ratio: 1:2- 1:3 
 
A427 
ATCC-HTB53  
Lung Adenocarcinoma DMEM Split ratio: 1:4 
K- Ras mut Glycin 
12 
A549 
ATCC-CCL185 
Lung Adenocarcinoma DMEM Split ratio: 1:10 
K- Ras mut Glycin 
12 
Calu-6 
ATCC-HTB56 
Lung Adenocarcinoma DMEM Split ratio: 1:6 
K- Ras mut Arg 61 
SKLU-1 
ATCC-HTB57 
Lung Adenocarcinoma DMEM Split ratio: 1:4 
K- Ras mut Glycin 
12 
CRL5883 
ATCC 
Lung Adenocarcinoma RPMI Split ratio: 1:3 
EGFR mut 
 
CRL2868 
ATCC 
Lung Adenocarcinoma RPMI Split ratio: 1:5 
EGFR mut 
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VL-2 
ICR 
Lung Large cell 
carcinoma 
DMEM Split ratio: 1:2 
K- Ras mut 
VL-4 
ICR 
Lung Large cell 
carcinoma 
DMEM Split ratio: 1:5 
K- Ras mut 
VL-10 
ICR 
Lung Squamous cell 
carcinoma 
RPMI Split ratio: 1:3 
K- Ras wt 
VL-3 
ICR 
Lung  Squamous cell 
carcinoma 
DMEM Split ratio: 1:4 
K- Ras wt 
VL-6 
ICR 
Lung 
metastasis 
in 
lymphnode 
Squamous cell 
carcinoma 
DMEM Split ratio: 1:4 
K- Ras wt 
VL-8 
ICR 
Lung 
metastasis 
in 
lymphnode 
Squamous cell 
carcinoma 
DMEM Split ratio: 1:3 
K- Ras wt 
VL-5 
ICR 
Lung 
metastasis 
in 
lymphnode 
Squamous cell 
carcinoma 
DMEM Split ratio: 1:5 
K- Ras wt 
VL-7 
ICR 
Lung 
metastasis 
in 
lymphnode 
Squamous cell 
carcinoma 
DMEM Split ratio: 1:2 
K- Ras wt 
293 
ATCC-CRL1573 
Kidney Embryonic DMEM Split ratio: 1:6 
constantly 
expressing parts of 
adenoviral genome 
(see Construction of 
adenoviruses) 
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Cre-8 Kidney  DMEM Split ratio: 1:9  
Derived from 293 
cells and were 
stably transfected 
with a cre 
recombinase gene 
Table 4: Overview of used cell lines with detailed information of origin, types and 
adequate medium for cultivation of cells 
 
ATCC American Type Culture Collection 
ICR Institute of Cancer Research, Vienna 
VL Vienna lung 
All cells are cultured in respective medium with 10% FCS in a humidified incubator at 
37°C with 7.5% CO2. 
Medium replacement and splitting of the cell are carried out according to the needs of 
the different cell lines.  
FCS Fetal Calf Serum, heat inactivated (PAA) 
DMEM Dulbecco's Modified Eagle Medium (Sigma) 
RPMI RPMI-1640 medium (Sigma) 
Trypsin/EDTA 
0.1% trypsin 
0.01% EDTA 
0.001% phenol red 
3.1.2 Storage of cells 
For freezing 50-60% confluent cells are washed with PBS and are trypsinized. 
Afterward cells get resuspended in 20-30ml medium and are pelleted by 
centrifugation at 1500rpm for 5 minutes (min). Medium is sucked of and cells are 
resuspended in 1ml serum containing 10%DMSO. Subsequently, cell suspension is 
transferred into a cryopreservation tubes (Nalgene, Cryoware). Cells are stored at  
-80°C for 2-3 days and afterwards finally put in liquid nitrogen for long term storage. 
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3.1.3 Growth curve 
Cells are infected with adequate amount of adenovirus and after 2 days equal 
amounts of cells were split into several 60mm dishes and are cultured in their 
appropriate medium with 10% FCS. Cells will be counted by using a microscope 
counting chamber every 1-3 days. For each time point 3 plates of cells were counted 
Counting chamber consist of 4 panels, which are divided in 4x4 squares. For cell 
counting, cells get trypsinized and cell suspension gets properly diluted. 10µl of this 
dilution get peptized between cover slip and counting chamber. Cells in each panel 
are counted separately and mean gets generated. To calculate the original 
concentration in cells per ml mean gets multiplied with the factor 104. 
Absolute cell number is calculated with following formula: 
 
 =  
 
 ∗ 10 ∗    
For calculating the doubling time of the cells following formula was used: 
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  =  ∗
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)
 
tW time in hours (h) between time point of counting 1 and time point of counting 2 
N1W number of cells at time point of counting 1 
N2W number of cells at time point of counting 2 
3.1.4 Construction of adenovirus 
Construction of an adenovirus was based on the Cre-lox recombination between ψ5 
virus and pAdlox vector containing the insert of interest.  
ψ5 virus is a version of Ad 5, which means that E1 and E3 genes are deleted. This 
virus contains loxP sites in the same orientation, flanking the packaging site (ψ). The 
packaging site can be removed by recombination between the loxP sites. The pAdlox 
shuttle plasmid is a derivate of pCMV Ad and contains the following sequences a left 
ITR, a packaging site (ψ), a CMV promoter, multiple cloning sites (MCS), loxP site for 
recombination and a right ITR. On both sites these sequences were flanked by Sfi I 
restriction sites. For selective propagation in bacteria these shuttle plasmid contains 
an ampicillin resistance cassette (Figure 7) (84). 
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Figure 7: Functional groups of the ψ5 adenovirus and the pAdlox plasmid (84) 
 
Selective Cre-8 cell line contains a β Actin based expression cassette driving the Cre 
recombinase from phage P1, with a N-terminal nuclear localization signal, which are 
integrated in 293 cells. 293 cells in general contain an integrated viral E1 region. This 
region contains all genes that are necessary for viral replication and therefore it is 
possible to propagate E1-deleted viruses.  
The DNA sequences which are inserted in the MCS of the pAdlox shuttle plasmid are 
included in recombinant virus in a Cre recombinase-catalyzed recombination event 
between pAdlox and ψ5. 
First a recombination between the two loxP sites in ψ5 was catalyzed by Cre 
recombinase. This leads to the removal of the cis-acting packaging sequence. The 
resulting viral genome is now unable to be encapsulated (ψ-). Then the pAdlox vector 
was digested by Sfi I restriction enzyme. This produces a linear DNA fragment 
containing 2 ITRs, a ψ signal, a loxP site and the target insert. Linear pAdlox 
fragments lead to higher yields of recombinant viruses compared to the circular 
plasmid. Next Cre recombinase catalyses recombination between ψ5 (ψ-) and the 
pAdlox fragment. The result is a recombinant virus with only one loxP site. 
Reinfection cycles lead to the loss of all ψ- viruses because of the wasting of their 
package signals, while the number of recombinant viruses will be increased (Figure 
8) (84).  
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Figure 8: The Cre recombinase-driven generation of adenoviruses (84) 
Creation of the target recombinant virus 
A PCR product or a DNA fragment derived from another vector, are ligated into the 
pAdlox backbone vector. 6µl of the plasmid are digested by Sfi I (see Restriction 
digestion & ligation) for 2 h at 50°C. For control of the restriction digestion an agarose 
gel is performed.  
3µg of the digested pAdlox shuttle plasmid are co-transfected with 1µg ψ5 virus DNA 
in Cre-8 cells (shuttle plasmid: virus DNA ratio 1:3). 
Fugene Transfection: 
Cre-8 cells are splited the day before in the ratio 1:5 so that the confluence on the 
next day was about 50%. Next day medium is reduced to the minimal necessary 
amount. In an eppendorf tube add 6µl of FuGene6 transfection reagent (Roche, 
#1815091) to 200µl medium (avoid even traces of serum) without touching the walls 
and incubate the mixture for 5 min at room temperature (RT). In a separate tube 
pAdlox shuttle plasmid and the ψ5 virus DNA are mixed together and FuGene 
medium solution can be added after and incubation time of 15 to 45 min at RT. 
Reagent solution should be added drop wise directly on the cells. 
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Propagation of the target recombinant virus 
After transfection and the first reinfection cycle cells are cultured 3 to 4 days, until 
they start to lyse at later reinfection cycles. Then they are scraped of and collected by 
centrifugation for 3 min at 1500rpm. The supernatant (SN) will be reduced to 2ml or 
discard and 2ml of 10mM Tris pH=8.8 is added. Afterwards virus is extracted by four 
to five rounds of freeze in N2 and thaw at 37°C in the water bath out of the cells. The 
sample will be centrifuged again for 3 min at 1500rpm before new Cre-8 cells, splitted 
one day prior to infection, are re-infected with less amount of virus-containing SN 
than before. 
After about 5 reinfections (rule: virus titer is than high enough, when 10µl of the SN of 
the re-infection before are enough to lyse the cells into 2 days), 15x 15cm cell culture 
dishes of 293 cells are infected with an adequate amount of virus derived from the 
last Cre-8 infection. When cells start to lyse, after about 2 to 3 days they will be 
scraped off and collected by centrifugation for 5 min at 1500rpm. SN was discarded 
and pellet is resuspended on 8ml 10mM Tris pH=8. For release of the virus cells are 
lysed by 5 cycles of freeze and thaw. After centrifugation (5 min, 1500rpm) the virus-
containing SN is collected and the virus is purified by density-gradient 
ultracentrifugation. Therefore SN is mixed with 5g CsCl, filled into an appropriate 
ultracentrifugal tube and is covered with a drop of mineral oil. Centrifugation is carried 
out in an ultracentrifuge at 32000rpm for 18-24 h at 10°C without brake. The purified 
virus is collected from the gradient using an 18G needle and is mixed with 2x storage 
buffer. The virus is stored in 200µl aliquots at -20°C. 
2x Storage buffer  
10mM Tris, pH=8 
100mM NaCl 
0.1% BSA 
50% glycerol 
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Measuring viral titer 
Viral titers are determined by measuring the optical density at 260nm (OD260). 15µl 
of the virus is mixed with 100µl 1x TE/0.1% SDS, vortexed rigorously for at least 30 
seconds (sec) and centrifugated 5 min at 13000rpm. For blank calibration 15µl of the 
blank solution is mixed with 100µl 1x TE/0.1% SDS and is treated as described 
above. Afterwards virus is measured at Thermoscientific NanoDrop 
microspectrophotometer. 
1 unit at 260nm ~ 1012 viral particles 
Blank solution  
0.5g/ml CsCl in 10mM Tris, pH=8; 2x Storage buffer = 1:1 
3.1.5 Adenoviral infection of cultured cells 
Cells are infected with an adequate dilution of the adenovirus, when they have 
reached a confluence of 50-70% and incubated 48 hours before harvesting. 
3.1.6 Infectivity test by using CFP expressing adenovirus 
For testing infectivity, the cells are infected with the recombinant virus expressing 
CFP (cyan fluorescent protein) and the infection efficiency is determined. Therefore 
3x 10cm dishes with equal numbers of cells are infected with 3 different CFP virus 
concentrations (low: 0.1µl, mid: 0.5µl, high: 1.5µl of the virus). After 48 hours blue 
cells are visualized under fluorescence microscope and infection efficiency is 
determined by percentage of blue fluorescence cells. Cell lines are categorized in 3 
classes: cells with low, middle and high infectivity rate.  
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3.2 Methods for working with DNA 
3.2.1 Polymerase chain reaction (PCR) 
PCR is used to amplify specific sequences of DNA to get higher amounts of DNA if 
they are necessary for further analysis. 
PCR components: 
xµl DNA 
5µl 10x Buffer 
1.25µl dNTPs (10mM) 
2µl Primer A (10µM) 
2µl Primer B (10µM) 
0.15µl AmpliTaq- Polymerase (Appplied Biosystems) 
xµl ddH2O to a total volume of 50µl 
PCR reaction 
Initial denaturation 1 min at 95°C 
Denaturation 30 sec at 95°C  
Annealing 30 sec at 59°C    32 cycles 
Extension 30 sec at 72°C 
Final extension 10 min at 72°C  
3.2.2 Phosphorylation of oligonucleotides 
For better annealing, oligonucleotides (oligos) were phosphorylated with ATP. 1µl 
oligonucleotides (100µM) and 14µl ddH20 are incubated at 70°C for 10 min. 
Afterwards oligos are placed on ice and 
2µl 10x PNK buffer 
2µl Polynucleotidekinase (AppliChem) (PNK) 
1µl ATP (1mM) 
are added. 
The mixture has to be incubated at 37°C for 1 hour. After this the PNK has to be 
inactivated (10 min at 65°C). 
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3.2.3 Annealing 
Annealing is the pairing of complementary of single stranded nucleic acids, resulting 
in a double stranded molecule. For the “pAdlox simiR 21” it was necessary to anneal 
two specific oligonucleotides to get the insert for the plasmid. 
For the annealing, 100µl of annealing buffer was added and the mixture was heated 
5 min at 98°C. To cool down slowly we switch the thermoblock of and wait until it 
reaches a temperature about 37°C. This step was repeated once.   
Annealing buffer: 
10mM Tris pH=8 
50mM NaCl 
1mM EDTA 
3.2.4 Agarose gel electrophoresis 
To check quality and quantity of PCR Products and plasmid DNA fragments agarose 
gel electrophoresis is performed.  
Preparation of the agarose gel 
Depending on the size of the analyzed DNA fragments 0.8 to 2% agarose gels are 
performed. Therefore the adequate amount of agarose is dissolved in ddH2O by 
boiling it in the microwave. Afterwards 50x TAE is added, so that it results in a final 
concentration of 1x TAE. After this the agarose solution is filled into a gel slide and a 
comb is inserted. After gel solidified the comb is removed and the electrophoresis 
tank is filled with 1x TAE. 
Gel electrophoresis 
DNA samples are mixed with an adequate amount of 6x sample loading buffer and 
are loaded into the slots. A λ marker or a low range DNA ladder (dependent on the 
size of the DNA fragment which should be detected) is loaded to evaluate DNA size 
by comparison. After electrophoresis is run by 70-100 V, DNA can be visualized by 
staining with an ethidium bromide solution (0.25µg/ml) for about 10 min. Then the 
DNA bands are detected under UV-screen. 
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1xTAE 
0.04M Tris acetate 
1mM EDTA 
in ddH2O 
pH=8.3 
6x sample loading buffer  
40% saccharose 
24% urea 
0.25% xylene blue 
0.25% bromphenol blue 
in 1x TAE 
λ marker 
λ DNA (Fermentas), digested by Hind III/ EcoR I  
For production of λ-marker 200µl λ DNA (0.3µg/µl), 42µl Buffer B (Roche, 10mM Tris-
HCl, 5mM MgCl2, 100mM NaCl, 1mM 2-Mercaptoethanol, pH=8.0), 4µl Hind III, 4µl 
EcoR I and 167µl ddH2O are mixed together and are incubated at 37°C over night 
(o/n). On the next day 83µl of 6x loading dye are added. Marker is stored at 4°C. 
Before loading, marker gets heated for a few minutes at 65°C.  
3.2.5 DNA extraction from agarose gel and DNA purification 
The DNA fragments of interest are cut out under the UV-screen. Then the agarose is 
dissolved and the DNA was obtained by purification with a column. For this 
Zymoclean Gel DNA Recovery Kit (Zymo Research) is used according to the 
manufacturer’s manual.  
Desalting is done with the use of Sephadex G50 or G25 (Mini Quick Spin DNA 
Columns and Mini Quick Spin OLIGO columns (Roche)). First the matrix of the 
columns is resuspended then it gets packed by centrifugation 1 min with 2000rpm. 
After this step the sample is added to the column bed and the column is again 
centrifuged for 3 min at 2000rpm. The eluate, which contains the DNA is collected in 
a tube. 
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3.2.6 Restriction digestion and ligation 
Enzyme restriction digestion is performed according to the conditions which are 
defined by the manufacturer company. For each restriction enzyme the adequate 10x 
reaction buffer (for buffer components see Table 5 and Table 6) is used. The reaction 
volume can differ between 20 to 50µl, dependent on the amounts of DNA. 
Buffer components Buffer A Buffer B Buffer L Buffer M Buffer H 
Tris-Acetate 33mM     
Tris- HCl  10mM 19mM 10mM 10mM 
MgCl2  5mM 10mM 10mM 10mM 
NaCl  100mM  50mM 100mM 
Mg Acetate 10mM     
K Acetate 66mM     
Dithioerythritol   1mM 1mM 1mM 
Dithiothreitol 0,5mM     
2-Mercaptoethanol  1mM    
Table 5: Composition of restriction digestion buffers (Roche); final concentration are 
given (10x buffers were diluted 1:10 in the final reaction) 
 
Buffer components Buffer 1 Buffer 2 Buffer 3 Buffer 4 
Bis-Tris-Propane-HCl 10mM    
Tris-HCl  10mM 50mM  
Tris-Acetate    20mM 
MgCl2 10mM 10Mm 10mM  
NaCl  50mM 100mM  
Mg Acetate    10mM 
K Acetate    50mM 
Dithiothreitol 1mM 1mM 1mM 1mM 
Table 6: Composition of restriction digestion buffers (New England Biolabs NEB); 
final concentrations are given (10xbuffers were diluted 1:10 in the final reaction 
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Used restriction enzymes 
Figure 7 gives an overview of used restriction enzymes in this study. 
Restriction 
enzyme 
Recognition 
sequence 
Cuts at 
Heat 
inactivation 
Company Buffer 
Bgl II  
(Bacillus 
globigii) 
A GATCT 37°C No Roche 
A: 100% 
B: 100% 
L: 25-50% 
M: 100% 
H: 100% 
Hind III  
(Haemophilus 
influenzae Rd 
com-10) 
A AGCTT 37°C 65°C; 15 min Roche 
A: 50-75% 
B: 100% 
L: 25-50% 
M: 100% 
H: 50-75% 
Nde I 
(Neisseria 
denitrificans) 
CA TATG 37°C 65°C; 20 min NEB 
1: 75% 
2: 100% 
3: 75% 
4: 100% 
Sal I 
(Streptomyces 
albus G) 
G TCGAC 37°C 65°C; 20 min NEB 
1: 0% 
2: 0% 
3: 100% 
4: 0% 
Sfi I 
(Streptomyces 
fimbriatus) 
GGCCNNNN 
NGGCC 
 
50°C No Roche 
A: 25-50% 
B: 25-50% 
L: 75-100% 
M: 100% 
H: 25-50% 
Xho I 
(Xanthomonas 
campestris) 
C TCGAG 
 
37°C No Roche 
A: 25-50% 
B: 75-100% 
L: 10-25% 
M: 25-50% 
H: 100% 
Table 7: Overview of used restriction enzymes and detailed information about them 
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Generally reaction (for reaction volume of 50µl): 
1-3µg DNA 
5µl 10x reaction buffer 
1µl restriction enzyme A 
1µl restriction enzyme B 
1µl BSA (if it was necessary for the activity of one of the restriction enzymes) 
xµl ddH2O to a final volume of 50µl 
Incubation for at least 1 h at the appropriate temperature (usually 37°C) 
Reaction for a control restriction digestion (to check if the correct plasmid was 
isolated): 
5µl of the STETL- Mini preparation (see DNA preparation) 
2µl 10x reaction buffer 
0.3µl restriction enzyme 1 
0.3µl restriction enzyme 2 
2,4µl ddH20 
Incubation between 30 min and 1 h at 37°C (except of restriction enzymes which 
need other temperature for their optimal activity) 
Sfi I digestion  
6µg DNA 
1µl Sfi I 
5µl 10x buffer M (Roche) 
xµl ddH2O to a final volume of 50µl 
Incubation at 50°C for 2 h 
Inactivation of restriction enzymes by phenol-chloroform-isoamylalcohol 
extraction 
Phenol-chloroform-isoamylalcohol (PCI) extraction was done to inactivate restriction 
enzymes, if they are not deactivatable by incubation at heat. 
Fill up the reaction to 100µl with ddH2O, add equal volume of PCI (49.5:49.5:1) and 
vortex rigorously. Afterwards centrifugation was carried out with 10000g at 4°C for 15 
min. The upper phase was collected and 2 volumes (V) of 100% cooled EtOH and 
0.1V 3M NaAc was added. The mixture was vortexted and incubated at -80°C for 30 
min or at -20°C o/n. After this centrifugation was carried out with 10000g at 4°C for 
15 min. SN was discarded and the pellet washed with 70% chilled EtOH. 
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Centrifugation was carried out as described before. SN was discarded and the pellet 
was dried for about 3 min at 65°C. Afterwards the DNA was dissolved in 25µl ddH2O. 
 
Dephosphorylation 
To minimize relegation of plasmid vectors the ends have to be dephosphorylated, 
using a Shrimp Alkaline Phosphatase (SAP) 
250ng Vector 
2µl SAP (Roche) 
2µl 10x reaction buffer 
xµl ddH2O to a final volume of 20µl 
Incubation at 37°C is carried for 15 min. Afterwards incubation at 65°C for 15 min is 
required to inactivate and remove the enzyme. For storage put the reaction directly to 
-20°C. 
Ligation 
Ligation of DNA fragments is achieved by usage of a T4-ligase at 16°C o/n. 
Different ligation approaches are done, using different DNA amounts and different 
ratios of insert to vector. 
The appropriate insert mass was calculated using the followed formula: 
() =  
 ∗  ℎ (!)

 ℎ (!)
∗ 
  () 
x W ratio vector: insert  
bpW basepairs 
Generally reaction 
25-50ng Vector  
xng Insert (dependent on the vector: insert ratio) 
2µl 10xbuffer  
1µl T4 Ligase (Roche) 
xµl ddH2O to a final volume of 20µl 
For standard ligations we use a 3:1 ratio of insert to plasmid. 
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3.2.7 Competent bacteria 
XL-1 bacteria are plated on LB Agar without Ampicillin (amp) and are incubated o/n 
at 37°C. Next day a single colony is inoculated in 2.5ml LB medium and under 
constant shaking of 180rpm at 37°C incubated o/n. On the next day bacteria are 
subcultivated in 250ml LB medium supplemented with 20mM MgSO4 and are left at 
37°C and constant shaking until the culture has reached a optical density of 0.4-0.6 
at 600nm. Then bacteria are pelleted (4500g, 5 min) and the SN is discarded. Pellet 
gets resuspended in cold LB medium and repelleted. The pellet is resuspended in 
chilled TFB1 buffer and incubated on ice for 5 min. Then the bacteria are 
centrifugated at 4500g for 5 min at 4°C to get a pellet again. This pellet is 
resuspended in 10ml of chilled TFB2. After an incubation of 30 min on ice, aliquots of 
300µl are stored at -80°C. 
TFB1  
30mM Kaliumacetate 
10mM CaCl2 
50mM MnCl2 
100mM RbCl 
15% glycerol 
in ddH2O 
adjust to pH=5.8 with 1M CH3COOH 
sterilize with a 0.45µm filter 
TFB2  
10mM N-morpholino propanesulfonic acid (MOPS) 
75mM CaCl2 
10mM RbCl 
15% glycerol 
in ddH2O 
adjust to pH=6.5 with 1M KOH 
sterilize with a 0.45µm filter 
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Transformation 
100µl XL-1 bacteria are added to maximal 20µl DNA and are incubated on ice for 20 
min. Transformation is done by heat shock: Bacteria and DNA are incubated for 90 
sec at 42°C, followed by incubation for 2 min on ice. Optional, transformation 
efficiency can be increased by performing a recovery time for the bacteria. Thus, 
500µl LB medium is added and bacteria are incubated for minimal 30 min at 37°C 
under constant shacking. Afterwards bacteria are centrifugated at 5000rpm for 2 min 
and 500µl of the SN is discarded. The pellet is resuspended in the remaining LB 
Medium. The bacteria are plated on selective LB agar containing 0.2 mg/ml amp and 
incubated o/n at 37°C.  
LB medium  
10g NaCl 
10g trypton 
5g yeast extract 
in 1l ddH2O 
Selective LB plates 
Dilute 15g Agar to 1l ddH2O and autoclave it. Afterwards let it cool down to 40-50°C 
and add 1ml antibiotics-stock [100mg/ml] (Ampicillin) 
3.2.8 DNA preparation 
STETL (Sucrose–Triton–EDTA–Tris-HCl–Lysozyme) MINI preparation 
A single colony of XL-1 bacteria is inoculated in 3ml LB Medium. Bacteria are 
incubated o/n at 37°C by constant shacking. Next day 1.5ml of this culture are 
pelleted by centrifugation at 10000g for 3 min at RT and the SN is discarded. Then 
the bacteria pellet is resuspended in 110µl STETL-buffer and incubated for 1 min at 
95°C. Afterwards bacteria are centrifugated by 10000g at 4°C for 10 min. The pellet 
is removed with an autoclaved toothpick, which is dipped in chilled RNase A before. 
Accordingly 110µl isopropanol are added and rigorously vortexed, following of 
centrifugation at 10000g for 15 min at 4°C. The SN is discarded and the pellet is 
washed with 200µl chilled 70% Ethanol by resuspension and centrifugation at 
10000g for 10 min at 4°C. After this the pellet is tried for 10 min at RT and 
resuspended in 30µl ddH2O. The DNA solution is stored at -20°C.  
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STETL buffer  
8% sucrose 
0.5% Triton X-100 
50mM Tris, pH=8 
50mM EDTA 
0.05% lysozyme (Roche), added freshly 
in ddH2O 
RNase A  
10mM Tris 
15mM NaCl 
5% Ribonuclease A (Sigma) 
in ddH2O 
Adjust to pH=7.55 
Heat for 15 minutes at 100°C 
MIDI preparation 
Bacteria are inoculated in 50 to 100ml selective LB Medium. This culture is incubated 
o/n at 37°C under constant shacking. On the next day MIDI preparation is carried out 
using Plus Midi kit (Quiagen) according to the manufactures manual.  
The concentration is determined by measuring with Thermoscientific NanoDrop 
microspectrophotometer by 260nm (1OD= 50 µg/ml). 
To confirm correct cloning, an aliquot of the plasmid is sent to Microsynth for 
sequencing. 
3.3 Methods for working with RNA 
For RNA work it is always necessary to wear gloves and use only 
Diethylpyrocarbonate (depC)-H20 to protect the RNA from degradation through 
RNAses. Additionally every working utensil is treated with 0.2M NaOH. 
DepC ddH2O  
DepC solution 1:1000 in ddH2O 
DepC ddH2O get incubated for 2 h at 37°C under constant shacking and get 
autoclaved twice. 
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3.3.1 Collection and storage of cultured mammalian cells for 
RNA isolation 
For RNA isolation a 15cm dish of cells is usually needed. The dishes are washed 
with 10ml chilled 1x PBS. After washing 1 ml 1x PBS is added, and the cells are 
scratched off with a scraper. The cell suspension is transferred into an eppendorf 
tube. Cells are then pelleted by centrifugation at 1000g for 5 min. After removing PBS 
cell pellets are immediately shock frozen in liquid nitrogen and can be further stored 
at -80°C. 
1xPBS 
137mM NaCl 
2.7mM KCl 
4.3mM Na2HPO4.2H2O 
1.4mM KH2PO4 
pH=7.4 in ddH2O 
3.3.2 RNA isolation 
500µl lysis buffer are added to the defrozen cell pellet. After resuspending the cells, 
lysis is achieved during an incubation period of 10 to 30 min at RT. 50µl 2M Na 
Acetate (pH=4) is added and the sample was mixed by vortexing. The same volume 
of chloroform: isoamylalcohol (24:1) is added and the sample is rigorously vortexed 
and incubated 5 min at ice. Afterwards separation of the phases is accelerated by a 
centrifugation at 12000g for 15 min at 4°C. The upper phase is transferred into a new 
tube and the same volume of PCI (49.5:49.5:1) is added. The sample is vortexed 
again and incubated for minimal 15 min on ice. The phases are separated by 
centrifugation at 12000g for 15 min at 4°C. Only the upper phase is carefully 
removed and collected into a new eppendorf tube. The chloroform: isoamlyalcohol 
extraction is repeated, followed by a second extraction with PCI. 
The RNA is precipitated by adding 1V of isopropanol. After the mixture is vortexed 
rigorously, incubation for 30 min at -20°C is carried out. The RNA is pelleted by 
centrifugation at 12000g for 15 min at 4°C. Afterwards the SN is carefully removed 
and the pellet is washed with 70% Ethanol. After an incubation of a few minutes at 
RT, RNA is again pelleted by centrifugation at 12000g for 10 min and SN is removed. 
The pellet is dissolved in 50µl depC ddH2O containing 1µl RNase inhibitor (RiboLock, 
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Fermentas) by incubation at 65°C for about 30 min under constant shacking of 
650rpm. 
Lysis buffer 
4M guanidinthiocyanat 
42mM sodium citrate 
2.5% polyvinylpyrolidone 
5% beta-mercaptoethanol, is added right before use 
10mM magnesium chloride, is added right before use 
3.3.3 MOPS gel electrophoresis 
Isolated RNA is visualized in a MOPS gel electrophoreses for controlling the quality 
of the RNA to exclude degradation on one hand, and to equalize the amounts of RNA 
for the Northern blot on the other hand.  
0.84g agarose are dissolved in 48ml depC-H2O and 6ml 10x MOPS by heating up 
the solution at a heating plate. After agarose is dissolved completely and solution is 
cooled down until it reaches a temperature about 60°C, 6ml formaldehyde is added 
and the solution is filled into a gel slide and a comb is inserted. After gel is harden the 
comb is removed and the gel is put into an electrophoresis tank, filled with 1x MOPS. 
Meanwhile RNA samples are prepared: 5µl RNA is mixed with 20µl RNA loading 
buffer and 1µl ethidium bromide solution (1:50 from stock solution of 1% EtBr 
(c=10mg/ml)). Before samples are loaded, they are heated for 1 minute at 65°C. Gel 
is run with a constant voltage of 70V. Meanwhile concentration is measured by 
Thermoscientific NanoDrop microspectrophotometer (1 OD= 40µg/ml). After the run 
of the gel is ready, the RNA is visualized under the UV screen and the equal amounts 
of RNA are determined by comparing their 28s and 18srRNA bands. Results are 
compared to the measurement of the Thermoscientific NanoDrop 
microspectrophotometer. 
If it is necessary, RNA can be enriched by extraction with 1-butanol. Therefore 1 
volume 1-butanol is added to the RNA and vortexed. To separate the phases 
centrifugation for 1 min at 10 000g and the upper phase (butanol phase) is discarded. 
This step can be repeated. Each time the water volume decreases. To finally remove 
the butanol rests a diethylether extraction is carried out. Therefore 500µl diethylether 
are added. Mixture is vortexed and centrifugated again. The upper phase is removed 
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and RNA is incubated in open eppendorf tube for a few minutes at 50°C until 
diethylether is evaporated. 
Afterwards RNA is aliquoted so that every sample contained the same amounts of 
total RNA (10-15µg) and equal volume of 2x loading buffer is added. Afterwards RNA 
is stored at -80°C until RNA separation gel is performed, but not longer than 2 to 4 
days. 
10xMOPS  
200mM MOPS 
50mM sodium acetate 
10mM EDTA 
in depC H2O 
RNA loading buffer  
50% formamide 
5.9% formaldehyde 
6.7% glycerol 
bromphenolblue until the solution is stained 
in 1xMOPS 
Ethidium bromide stock solution [10mg/ml] in ddH2O 
3.3.4 RNA polyacrylamide gel electrophoresis (PAGE) for 
miRNAs 
For miRNA size separation an 18% RNA PAGE gel containing 7.6M urea is 
performed. Therefore 4.5g urea (or 2.35g when acrylamide already contains urea 
(c=500g/l)) is dissolved in 4.5ml acrylamide (40%, 19:1) and 2ml 5xTBE by heating. 
While dissolving urea the gel equipment is prepared. Therefore two glass plates with 
spacer in between are assembled in a cassette and are stacked into a casting stand. 
After urea is completely dissolved the solution is filled up to 10ml with depC ddH2O 
and when it is cooled down 100µl 10% APS and 4µl TEMED are added. Then 
immediately the solution is poured between the glass plates and a comb is inserted. 
After polymerization the gel is put into a tank filled with 1xTBE running buffer. Comb 
is removed and the slots are rinsed with running buffer using a string. The pre-run of 
the gel is carried out in the constant ampere modus (25mA) until buffer has reached 
about 50°C, which took about one hour. Meanwhile the RNA samples are prepared 
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by thawing them on ice and putting them on 65°C until they are completely in 
solution. A tRNA sample is prepared as a positive control, too.  
The prepared RNA samples are incubated for 5 min at 70°C. Before loading the 
samples the slots are rinsed again with running buffer. The electrophoresis is carried 
out at constant 80V.  
2x loading buffer 
10ml formamide 
200µl 0.5M EDTA pH=8 
1mg Bromphenolblue 
5xTBE 
1.1M Tris 
900mM Borate 
25mM EDTA 
in depC ddH2O 
Tris  Tris-(hydromethyl)-aminomethane 
APS   Ammoniumpersulfate 
TEMED N,N,N‘,N‘-Tetramethylethylenediamine 
3.3.5 Northern blotting 
RNA Transfer 
For transferring the RNA from the gel to the nylon membrane a sandwich consisting 
of a sponge, 2 layers of 3MM whatman paper, PAGE gel, nylone membrane, again 2 
layers of 3MM whatman paper and sponge are assembled. All components expect of 
the PAGE gel are wetted with DepC ddH2O before assembling. For elimination of 
disturbing air bubbles, a plastic pipette is rolled over the blot.  
The blotting cassette is put into the blotting tank, which is filled with 0.5x TBE. 
Blotting was carried out o/n at 150mA at 4°C under constant stirring. The RNA was 
transferred to the nylon membrane from the negative cathode to the positive anode. 
Nylon membrane GeneScreen Plus® Hybridization Transfer Membrane, pore 
size 45µm 
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Crosslinking and Methylenblue staining 
On the next day transfer is disassembled and the membrane is put on a dry filter 
paper and RNA is cosslinked to the membrane (Autocrosslink 1200+100µJ energy) in 
a Stratagene Crosslinker. 
For control of the transfer and exclusion of degradation of the RNA while 
electrophoresis the membrane is stained with methylenblue until rRNA bands are 
visible and washed with ddH2O. Photography is taken to document the amounts and 
quality of RNA. Afterwards membrane is washed again with ddH2O and is stored in 
foil at -20°C for further procedure.  
Methylene blue  
0.04% methylene blue 
in 0.5M sodium acetate (pH=5.2) 
Pre-hybridization 
Hybridization oven is heated to 42°C and hybridization buffer is preheated. 
A freezer bag is cut open and one 1MM whatman paper is placed on it. The 1MM 
whatman paper is soaked with hybridization buffer and the nylon membrane with the 
RNA side up is put on the paper. Another 1MM paper is placed on the membrane 
and soaked with hybridization buffer containing t-RNA (0.1mg/ml). The next 
membrane can be put on the 1MM whatman paper with RNA side down. Then 
another 1MM whatman paper can be put on the second membrane. The sandwich 
can contain up to 10 membranes spaced by 1MM whatman paper soaked with 
hybridization buffer containing tRNA, but the outer layer of the sandwich must be 
1MM whatman paper. Finally the sandwich is heat sealed in the freezer bag and 
airbubbles get eliminated by crop out, followed by putting the sandwich into another 
plastic bag. The sandwich was placed into the hybridization oven and was incubated 
at 42°C 2 to 20 hours.  
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Hybridization solution  
5x SSPE 
0.1M Natriumphosphate pH=6.5 
50% Formamide 
5x Denhardt’s 
10mM EDTA pH=8 
1% Sarkosyl (Sigma) 
20x SSPE  
3.6M NaCl 
200mM NaH2PO4 
20mM EDTA pH=8 
50x Denhardt’s  
1% BSA 
1% Polyvinylpyrrolidan 
1% Ficoll 
Probe labeling and hybridization 
2µl DNA probe (10µM) are mixed with 10µl ddH2O and incubated for 10 min at 70°C. 
Afterwards probe is immediately placed on ice and 2µl 10xPNK buffer is added. At a 
space certified for working with radioactive material 5µl gamma 32P-ATP (3000 to 
6000 Ci/mmole) and 1µl T4 Polynukleotidkinase (PNK) are added. Probe is 
incubated at 37°C for 1 hour, to inactivate PNK subsequently the sample is incubated 
at 65°C for 10 min. Afterwards 30µl ddH2O are added and probe is cleaned by using 
a G25 sepharose column. Incubation is carried at 95°C for 5 minutes to denature 
probe. After this, probe is placed on ice. Dependent on the expected signal intensity, 
one probe is enough for hybridization of 2 to 10 membranes.  
Hybridization is carried out as described in pre-hybridization but the hybridization 
buffer contains additionally the labeled probe. The sealed sandwich is incubated o/n 
at 42°C in the hybridization oven. 
Washing 
All washing steps are carried out at 50°C. Sealed sandwich is cut open and 
membrane is put into glass tubes. First non stringent washing buffer is added to rinse 
the membrane. Then the washing buffer is discarded and new non stringent buffer is 
added and the membrane is incubated for about 15 min in the hybridization oven by 
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rotating. Repeat this step twice and wash membrane about 30 min each time. 
Afterwards the membrane is washed with stringent washing buffer for about 20 to 60 
min. 
Non stringent wash buffer 
3x SSC 
25mM NaH2PO4 pH=7.5 
5% SDS 
In ddH2O 
Stringent wash buffer 
1xSSC (15mM NaCl, 1,5mM sodium citrate) 
1% SDS 
in ddH2O 
Detection of Northern blot 
For detection the washed membranes are heat sealed into foil and are incubated for 
6 hours (for U6) to 4 days (for miR-21) in a storage phosphor screen (Amersham 
Biosciences). The RNA bands are detected with a phosphor imager screen 
(Typhoon). 
Quantification 
Quantification of RNA bands are done with Image Quant 5.0 software by background 
correction.  
3.4 Methods working with proteins 
3.4.1 Isolation of total protein and determination of protein 
concentration 
Cells are harvest as described before, but the cell amount growing in a 10cm dish is 
sufficient (see harvesting cells for RNA isolation). Cell pellet is resuspended in chilled 
protein lyses buffer (TGH buffer) and incubated for 10 to 30 minutes on ice. 
Afterwards cell lysate is treated for 3 minutes by sonication in water bath. Cell debris 
is then removed by centrifugation at 14000rpm at 4°C for 10 min. SN, containing the 
proteins, is transferred into a new tube and an aliquot is used for determination of 
protein concentration. 
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The concentration of protein is measured using Micro BCA Protein Assay Reagent 
Kit (Pierce). 2.5µl of the protein lysate are mixed with the reagents of the kit 
according to the manufactures manual. After incubation of 2 hours at 37°C, protein 
concentration is determined by absorbance measurement at 562nm and is compared 
with a BSA protein standard curve containing 0µg/ml to 200µg/ml BSA. 
TGH protein lysis buffer 
50mM Hepes 
150mM NaCl 
1mM EDTA 
10mM NaF 
1.5mM MgCl2 
10% glycerol 
1% Triton X-100 
0.5mM Sodium-vandate (added freshly) 
2.5% Complete (Roche) (added freshly) 
1µM PMSF (added freshly) 
in ddH2O 
3.4.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS PAGE) 
In SDS PAGE protein are separated by their molecular weight.  
Preparation of polyacrylamide gel 
For coomassie-staining small SDS PAGE gels (7.2x10.2cm) are done, while for 
western blotting 11-13% gels with the size of 16x18cm are performed. Therefore two 
glass plates with plastic spacer in between are assembled in a cassette and were 
stacked into a casting stand. The separation gel is poured between the two glass 
plates and immediately overlaid with isopropanol to avoid the gel from exposure to O2 
and produce even surface. After polymerization isopropanol is removed completely, 
the stacking gel is poured on the separation gel and a comb is inserted. After 
polymerization of the stacking gel comb is removed and electrophoresis is carried 
out.  
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15x18cm   
Separation Gel: 11%  stacking gel: 5% 
8.25ml Aa (37:1) 1.275ml Aa (37:1) 
7.5ml Tris pH= 8.8 1.2ml Tris pH= 8.8 
150µl 20% SDS 50µl 20% SDS 
300µl 10% APS 100µl 10% APS 
12µl TEMED 10µl TEMED 
13.8µl ddH2O 7.3ml ddH2O 
Volume=30ml Volume=10ml 
 
7.2x10.2cm   
Separation Gel: 11%  stacking gel: 5% 
2.89ml  Aa (37:1) 446µl Aa (37:1) 
2.68 ml Tris pH= 8.8 420µll Tris pH= 8.8 
52.5µl 20% SDS 17.5µl 20% SDS 
105µl 10% APS 35µl 10% APS 
4.2µl TEMED 3.5µl TEMED 
4.83µl ddH2O 2.56µl ddH2O 
Volume=10.5ml Volume=3.5ml 
Aa  37.1% Acrylamide, 1% Bis-acrylamide 
SDS  Sodium dodecylsulfate 
Tris  Tris-(hydromethyl)-aminomethane 
APS  Ammoniumpersulfate 
TEMED N,N,N‘,N‘-Tetramethylethylenediamine 
Electrophoresis 
Gel is put into an electrophoresis chamber and the inner space of this as well as half 
of the container is filled with 1x electrophoresis buffer. Equal amounts of total protein 
are mixed with adequate volume of 4x sample loading buffer. Proteins are 
denaturated by incubation for 10 min at 95°C. The samples and the marker 
(Presicion Plus ProteinTM Standards–All Blue, BioRad) are loaded into the slots. 
Electrophoresis is carried out maximal 150V in the constant voltage mode from the 
cathode (-) to the anode (+). 
  
50 
 
1x Electrophoresis buffer  
50mM Tris 
0.19M Glycine 
3.5mM SDS 
in ddH2O 
4x Sample loading buffer  
40% Glycerine 
5% 2-Mercaptoethanol 
9.2% SDS 
250mM Tris, pH=6.8 
Bromphenolblue (until the solution was stained) 
in ddH2O 
3.4.3 Coomassie-staining 
Coomassie-staining allows visualization of small amounts of proteins. It can be used 
to verify measured protein concentrations and check quality of the preparation.  
After electrophoresis gel is put into a glass container and staining solution was 
added. For accelerating the staining process the solution can be heated for a few sec 
in the microwave and then is incubated for 10 to 30 min. After incubation staining 
solution is discarded and gel is incubated o/n in destaining solution. This process can 
be accelerated by warming up the solution. On the next day a photograph is taken 
and protein concentrations are adjusted. Gel can be tried between a foil.  
Staining solution 
30% Methanol 
10% acetic acid 
Coomassie blue until the solution is stained 
Destaining solution 
30% Methanol 
10% Ethanol 
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3.4.4 Western blotting 
Protein transfer 
For protein transfer from PAGE to nitrocellulose membrane a sandwich consisting of 
a sponge, 2 layers of 3MM whatman paper, PAGE gel, nitrocellulose membrane, 
again 2 layers of 3MM whatman paper and sponge are assembled. All components 
expect of the PAGE gel are wetted with 1x transfer buffer before assembling. For 
elimination of disturbing air bubbles, a plastic pipette is rolled over the blot.  
The blotting cassette is put into the blotting tank, which is filled with 1x transfer buffer. 
Under constant stirring blotting is carried out at 400mA in constant ampere mode at 
4°C for at least 7 hours (better o/n). The protein is transferred to the nitrocellulose 
membrane from the negative cathode (-) to the positive anode (+). 
1x Transfer buffer  
48mM Tris 
39mM Glycine 
0.037% SDS 
20% Methanol 
in ddH2O 
Nitrocellulose membrane PROTAN original nitrocellulose ROLLS, BA83, pore 
size 0,2µm 
Ponceau staining 
After transfer membrane is washed to remove the transfer buffer and is stained with 
Ponceau-red solution until the protein bands get visible. Afterwards membrane gets 
de-stained with 1xTBST until all of the Ponceau-red solution was removed.  
10xTBS 
250mM Tris 
1.37 M NaCl 
27mM KCl 
pH=7.6 
in ddH2O 
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1xTBST  
10% 10xTBS 
0.1% Tween20 (BioRad) 
in ddH2O 
Ponceau-red solution 
0.1% Ponceau-red 
5% acetic acid 
In ddH2O 
Solution should be stored at 4°C and can be used several times. 
Immunostaining 
To minimize unspecific signals membrane is incubated in blocking solution for at 
least 1 hour. After washing 2 times with 1xTBST, membrane is incubated in primary 
antibody with an adequate dilution of the primary antibody o/n at 4°C. Afterwards 
membrane is washed for 2-3 times with 1xTBST, each at least 10 min, followed by 
incubation with secondary antibody (dilution: 1:5000) for about 1 hour at RT. Finally 
membrane is washed again 2-3 times with 1xTBST. If there is a lot of background 
signal, membrane is washed once with TNN buffer for at least 15 min and twice with 
1xTBST, each time for at least 20 min. 
Blocking solution 
5% non fat dry milk powder 
in 1xTBST 
TNN buffer  
50mM Tris, pH=7.5 
250mM NaCl 
5mM EDTA 
50mM NaF 
0.5% NP-40 
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Used Antibodies 
rabbit anti-Spry1, established by group of Dr. Sutterlüty (dilution 1:100) 
rabbit anti-Spry2, established by group of Dr. Sutterlüty (dilution 1:250) 
rabbit anti-Erk1/2, Upstate (dilution 1:5000) 
mouse anti-β Actin, Novus Biological (dilution 1:20000) 
rabbit anti-PTEN, Epitomics (dilution 1: 1000) 
rabbit anti-PDCD4, Epitomics (dilution 1:5000) 
rabbit anti- Au5, Bethyl Laboratories, TX, USA (1:6000)  
anti-mouse IgG, Pierce (#31450)  
anti-rabbit IgG, Pierce (#31463) 
Primary antibody dilution 
Primary antibody in adequate dilution 
1% BSA 
0.1% NaN3 
in 1xPBS 
is stored at 4°C and used several times for different membranes 
Secondary antibody dilution 
1:5 000 anti mouse IgG or anti rabbit IgG 
2% milk 
in 1xTBST 
is made freshly 
Analysis  
The secondary antibody is conjugated to horseradish peroxidase (HRP) to visualize 
proteins by chemiluminescence. Therefore 10ml of ECL solution 1 is mixed with 30µl 
ECL solution 2 and membrane is incubated in this detection solution for 1 min. 
Membrane is placed between two plastic foils and air bubbles are removed. The x-
ray film is put on the top for an adequate period of time which mainly depends on the 
primary antibody to detect emitted light. After detection membrane is washed 2-3 
times with 1x TBST to remove the detection solution completely.  
ECL solution 1  
200mM p-Coumaric acid 
1.25mM Luminol 
in 0.1M Tris, pH=8.8 
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ECL solution 2  
3% H2O2 
Further treatment 
Membranes are incubated several times in different antibodies. Each time the 
procedure is done as described in Immunostaining. 
If membrane is not used for a longer time, it get dried and stored at RT. For 
reactivation, membrane is incubated in 1xPBS for 5 min.  
Quantification 
Quantification of RNA bands are done with Image Quant 5.0 software by background 
correction.  
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Concerning tumor entities, miR-21 expression of cell lines derived from 
adenocarcinoma and squamous cell carcinoma were analyzed and compared by 
performing a box blot diagram. Figure 11 shows that on average cell lines derived 
from adenocarcinoma have higher levels of miR-21 (on average 1.3 fold increased 
compared to WI-38) than cell lines derived from squamous cell carcinomas (on 
average 0.82 fold decreased compared to WI-38), although no statistical significance 
can be observed (p=0.1134).  
 
Figure 11: MiR-21 expression of cell lines derived from adenocarcinoma or 
squamous cell carcinoma. Expression data observed from Northern blots were 
grouped into miR-21 expression from adenocarcinoma and squamous cell 
carcinoma. 
 
4.2 Influence of oncogenic mutations on miR-21 
expression 
To analyze the influence of intrinsic factors on miR-21 expression, cell lines with 
oncogenic mutations in EGFR where compared with their wt counterparts. MiR-21 
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without an EGFR mutation were depicted in a box blot diagram. As shown in Figure 
12 no difference in miR-21 levels can be observed. MiR-21 levels of cell lines 
harboring an EGFR mutation are on average 1.05 fold increased compared to WI-38, 
while cells with the wt of this gene show a mean of 1.06. 
 
Figure 12: MiR-21 expression of cells with EGFR mutation compared to cells with 
the wt form of this gene 
 
Additionally, cell lines were classified into cells carrying a K-Ras mutation (A427, VL-
2, VL-4, A549, Calu-6, SKLU-1) and cells which harbor the wt of the gene. Detection 
of miR-21 shows that cells which carry the mutation have on average higher miR-21 
levels (mean±SEM= 1.30±0.17) than these with the wt gene (mean±SEM= 
0.87±0.13) although the difference in miR-21 expression does not show significance 
(p=0.0853), possibly due to the small sample size (Figure 13A).  
To investigate if oncogenic Ras have an influence on miR-21 expression, oncogenic 
H-Ras V12, K-Ras V12 and N-Ras N61 viruses, with an Au5 tag were expressed in 
WI-38, cells were harvest 48 hours after infection and miR-21 expression was 
detected by Northern blot. For equal loading, Northern blot for U6 was performed too 
(Figure 13B). 
To verify the expression of oncogenic Ras, Western blot was performed. Since the 
ectopic proteins were epitop tagged, Au5 antibody was used to verify their 
expression. As loading control β Actin was used (Figure 13D). 
None of the oncogenic Ras isoforms influences the expression of miR-21 in WI-38 
cells, which indicates that Ras is not an important determinant of miR-21 expression 
(Figure 13C). 
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4.3 Correlation of miR-21 levels with its 
substrates 
PTEN, PDCD4 and Spry1 and Spry2 were found to be targets of miR-21 (29). To 
figure out if there is a correlation between the expression of these proteins and miR-
21 levels in NSCLC-derived cell lines, Western blots were performed.  
4.3.1 Endogenous expression of PTEN and PDCD4 and its 
correlation with miR-21 levels in NSCLC-derived cell lines: 
To determine PTEN and PDCD4 amounts in cell lines, cells were harvest at 90% 
confluence, total protein was isolated and the protein concentrations were measured. 
150µg of protein was loaded on SDS gel for analysis by Western blot. For control of 
equal loading, Ponceau red staining was performed, following by incubation of the 
membrane first in PTEN and afterwards in PDCD4 antibody (Figure 14A). 
While in all cell lines detectable amounts of PTEN are observed, only a few cell lines 
express PDCD4. 
Due to the fact, that not all cell lines have detectable amounts of PDCD4, they were 
grouped in two classes: in used cell lines either express PDCD4 like VL-6, VL-7, VL-
10, CRL5883 and CRL2868 and cell lines which do not. No correlation between 
expression of PDCD4 and miR-21 levels was found (Figure 14B). Both groups show 
on average the same amounts of miR-21. 
 
To correlate PTEN levels with the expression of miR-21, cell lines were classified into 
two classes: low and high expressers. Cell lines with low PTEN levels are A427, VL-
3, VL-8, CRL5883 and SKLU-1, while VL-6, VL-7, A549, VL-5, CRL2868, Calu-6, VL-
10 and VL-2 express more PTEN (Figure 14A).  
On average cell lines with a lower expression of PTEN show nearly the same miR-21 
levels (mean±SEM= 1.08±0.23) than cells with higher PTEN levels (mean±SEM= 
1.03±0.15). No connection between PTEN expression and miR-21 levels can be 
observed (Figure 14C).  
 
 Figure 14: Correlation between expression of PTEN and PDCD4 and levels of miR
21. A: One representative of 2 blots analyzing endogenous levels of PTEN and 
PDCD4 in different NSCLC-
depicted as loading control
connection with PDCD4; Dat
Northern blots per cell line, respectively.
in connection with PTEN; Data were 
Northern blots per cell line, respectively.
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In addition Western blots were carried out to confirm the overexpression of Spry 
proteins (Figure 17C+ D).  
Although overexpression of Spry1 is obvious (Figure 17C), detection of miR-21/ U6 
ratio shows that there is no difference in miR-21 levels after overexpression of Spry1 
(Figure 17B).  
Overexpression of Spry2 with fewer amounts does not lead to an alteration in miR-21 
expression. Only overexpression of Spry2 with the highest concentration show a 
significant (p=0.008) decrease of miR-21 expression compared to control cells 
(Figure 17B). Overexpression of Spry2 can be confirmed via Western blot (Figure 
17D). 
4.5 Modulation of miR-21 levels 
4.5.1 Preparatory experiments 
4.5.1.1 Infectivity assay by using CFP expressing adenovirus 
For further experiments it was necessary to construct a control virus to exclude 
general viral effects.  
To construct the control virus an existing pAdlox CFP plasmid was digested with Sfi I 
and the virus was constructed like it is described in material and methods. Before the 
cells were harvested for viral reinfection, photographs with the fluorescent 
microscope were taken.  
After transfection there are only a few transfected cells, which incorporated and 
expressed the transfected pAdlox CFP plasmid. Due to the low titer in the first round 
of virus generation, 3 days after infection with the crude lysate no blue fluorescent 
cells were visible. Nonetheless cells were harvested and after the second reinfection 
there were a lot of fluorescent cells, indicating that most cells were infected with the 
generated recombinant virus. In the consecutive rounds of infections nearly all cells 
were infected. To assure that there are no original ψ5 viruses contaminating the viral 
preparation, in total five reinfection cycles were performed (Figure 18). Each time the 
viral titer of recombinant CFP viruses increased as concluded from a clearly more 
effective. 
  
 Figure 18: Generation of recombinant adenoviruses is monitored by picturing CFP 
expressing cells with a fluorescence microscope. Cells were pictured 48 h after 
transfection or infection with a crude cell extract harboring the viruses. Reinfection 
cycle is indicated. To visualize the number of monitored cells pictures with bright field 
were taken. 
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For evaluation infection efficiency of the cell lines planned to use for further analysis, 
and as initial experiment adenovirus infectivity test was performed Therefore WI-38 
and NSCLC-derived cell lines were infected with three different concentrations of the 
recombinant CFP virus and 48 hours later photographs were taken with a fluorescent 
microscope and infection rate was determined as percentage of blue fluorescent 
cells. Afterwards cell lines were classified into 4 categories: high, middle, low and non 
infection efficiency (Table 8). 
Cell lines Infection efficiency 
WI-38 high 
A427 middle 
A549 middle 
Calu-6 middle 
VL-2 low 
VL-3 low 
VL-6 middle 
VL-7 no 
VL-10 low 
VL-5 middle 
VL-8 high 
VL-4 middle 
SKLU-1 no 
Table 8: Infection efficiency of CFP virus in different NSCLC derived cell lines 
Examples of all these categories are shown in Figure 19. As example for cells which 
are low infection rate VL-3, for middle infection efficiency A427 and for high VL-8 
were chosen. 
  
  
Figure 19: Examples for cell lines defined as high (VL
(VL-3) susceptible are depicted. Images of cells infected with the low, middle and 
high CFP virus concentration are shown.
 
  
-8), middle (A427), and low 
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4.5.1.2 Adenoviral influence on expression of miR-21 
Since adenoviruses are lytic viruses, cells show sometimes a general viral effect, 
which can influence the results of the experiments and can lead to problems with 
experimental interpretation. To exclude a general viral effect at the chosen titer, it 
was examined if there is a difference in miR-21 expression between uninfected cells 
and those infected with the control virus. 
Therefore one plate of cells was infected with the control virus while another one was 
left untreated, 48 hours postinfection cells were harvest and Northern blot for 
detection of miR-21 was performed. Afterwards miR-21/ U6 ratio was analyzed via 
Image Quant 5.0 software to compare miR-21 expression in uninfected cells and 
cells which are infected with the control virus.  
Although the difference between miR-21 levels in this two cell populations varied due 
to experimental differences between 0.4 and 1.8, on average no effect of the control 
virus in miR-21 expression compared to uninfected cells can be observed (Figure 
20).   
Due to the result, in further experiments expression of uninfected and cells infected 
with a control virus were combined to one control value.  
 
Figure 20: Quantification of miR-21/ U6 ratio from 10 Northern blots. Analysis was 
done with Image Quant 5.0 software. Expression of cells infected with the control 
virus is randomly set to 1. 
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4.5.1.3 Preparation of the constructs for modulation of miR-21 
expression 
For overexpression of miR-21, a pAdlox plasmid containing a fragment of the primiR 
21 was already available in the labor. The fragment of the primiR 21 used to 
overexpress miR-21 includes premiR-21 and about 200 nt flanking sequences 3’ as 
well as 5’ of the loop. Vector map can be found in the appendix. 
 
For inhibition of miR-21 three different strategies were used: 
pAdlox sponge eraser 21 was already available at the begin of the study and is a so 
called sponge. The plasmid contains a CMV promoter, where RNA polymerase II can 
bind. As substrate, luciferase reporter followed by a tandem of an antisense 
sequence for miR-21 is included. Vector map of the construct can be found in 
appendix.  
pAdlox oligo eraser 21 contains a U6 promoter where RNA polymerase III can bind. 
In contrast to pAdlox sponge eraser 21 the new plasmid contains no luciferase 
reporter and only one antisense sequence for miR-21.   
In order to clone pAdlox oligo eraser 21, U6 promoter was amplified via PCR from 
another plasmid (pSilencer). After successful amplification, insert (=U6 promoter) 
was digested with Xho I and Sal I to generate compatible ends to the vector for 
ligation (Figure 21A).  
The vector pAdlox sponge eraser 21 was digested with Xho I to remove the CMV 
promoter. The resulting fragments with the size of 2333 bp and 3592 bp are shown. 
DNA from vector fragment of size 3592 bp was eluted from the gel (Figure 21B). To 
disable religation of the vector, the ends were dephosphorylated. For the control of 
restriction digestion and gel elution, agarose gel electrophoresis was performed for 
the insert and the vector.  
Afterwards ligation was performed, following by transformation in competent E. coli. 
To purify cloned plasmid, STETL preparation of the plasmid DNA was performed and 
control digestions were done with Bgl II and Nde I. Agarose gel electrophoresis was 
carried out to verify correct cloning and correct direction of the insert. Digestion of 
pAdlox oligo eraser 21 results in 2 fragments with the size of 3495 bp and 369 bp, 
while digestion of pAdlox sponge eraser 21 leads to fragments of 2371 bp and 3554 
bp. Gel electrophoreses shows clones (1-3) which were not correct. Clone 4 shows 
 the two fragments which were expected and 
verify the sequence, MIDI preparation was performed and an aliquot of DNA was 
sent to Microsynth for sequencing.
Figure 21: Control of pAdlox oligo eraser
promoter (insert) digested with Xho
ladder (L= ladder is MassRuler Low Range D
the vector (pAdlox sponge eraser
DNA Ladder) C: Different clones after a control digestion with Bgl
shown D: λ DNA ladder E: MassRuler low range DNA ladder (Fermentas)
identify correct clones
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pAdlox simiR 21 should inhibit miR-21 expression by producing siRNA against primiR 
21, which should lower the level of mature miR-21. 
pAdlox simiR 21 was cloned using pAdlox oligo eraser 21 as backbone. Therefore 
pAdlox oligo eraser 21 (= vector) was digested with Xho I and Bgl II, resulting in two 
fragments with the size of 3567 bp and 297 bp (Figure 22A). The removed 297 bp 
contains the eraser and part of the polyadenylation signal. Afterwards restriction 
enzymes were deactivated by PCI extraction and agarose gel electrophoresis was 
performed. The band with the size of 3567 bp was eluted from the gel by DNA gel 
recovery kit.  
Meanwhile two complementary primers were annealed to create the simiR 21 insert 
with compatible overhangs to the digested vector. To facilitate ligation primers were 
phosphorylated and annealing was carried out. Fragments were purified by 
Sephadex column to elude all ingredients which can annoy the ligation.  
Ligation, followed by transformation with recovery time for bacteria in competent E. 
coli was performed. Different concentrations were used and a 9:1 insert/ vector ratio 
using 25ng vector was most successful. 3 clones compared to 0 clones with the 
control ligation were obtained. STETL preparation of 3 clones was carried out and 
control digestion first with Hind III and afterwards with Sfi I was performed. All picked 
clones showed 3 fragments at a size comparable to the calculated fragments sizes of 
2528 bp, 865 bp and 253 bp (Figure 22B). The original backbone vector (pAdlox 
oligo eraser 21) was included as control and yielded two fragments (2528 bp and 
1336 bp) as visible at the agarose gel. 
For verification the plasmid, MIDI preparation was performed and an aliquot of the 
plasmid was sent for sequencing.  
Preparation of adenovirus of the pAdlox oligo eraser 21 and pAdlox simiR 21 
construct was done as described in material and methods.  
 
 Figure 22: Construction of pAdlox simiR 
(pAdlox oligo eraser 21) was digested with Xho
Low Range DNA ladder) B: 
Sfi I are shown (C= control, original vector; L= ladder is λ DNA ladder) 
ladder D: MassRuler low range DNA ladder (Fermentas)
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4.5.2 Influence of overexpression of miR-21 on proliferation 
First a growth curve in A459 was performed to examine the influence of miR-21 
expression on proliferation. Therefore cells were infected with adenoviruses 
generated through recombination with pAdlox primiR 21 and with a control virus. 2 
days afterwards, cells were counted and equal amounts of cells were split into 6cm 
dishes. For a week, every day triplicates of these cells were counted to follow their 
proliferation.  
Results were analyzed and are shown in Figure 23A. Between the cells, infected with 
the control virus and cells which should have higher expression of miR-21, no 
difference in proliferation can be found.  
To control if the pAdlox primiR 21 virus works correct, cells were infected with the 
virus and after 2 days they were harvest and RNA was isolated. After performing 
Northern blot, it was shown that there was no increase of miR-21 expression in cells 
infected with pAdlox primiR 21 virus (Figure 23B). In contrast to the supposed results 
miR-21 in the analyzed cells infected with the highest concentration of the virus 
decrease 0.3 fold compared to control cells. To exclude that the construct only works 
on protein level, Western blot of cells infected with pAdlox primiR 21 was performed. 
Spry1 and Spry2 expressions both targets of miR-21 were examined. The results 
were similar to the results maintained from the Northern blot before, which means 
that also at protein level no difference between cells which were infected with the 
primiR 21 virus and control cells can be found (Figure 23C+D). Neither Spry1 nor 
Spry2 is decreased compared to control cells, no matter which concentration of 
pAdlox primiR 21 virus was used.  
Therefore we considered that the viral recombination was not as efficient as expected 
and we decided to repeat the production. Cre8 cells were transfected with the primiR 
21 plasmid and empty virus. Construction of adenovirus was carried out, as 
described in material and methods. After purification U373 cells were infected with 3 
different concentrations of the newly prepared virus, and 48 hours postinfected cells 
were harvested. Afterwards RNA was isolated and miR-21 and U6 levels were 
detected by Northern blot. 
  
 Figure 23: Infection of A549 cells with adenoviruses exp
were infected with pAdlox primiR 21 adenovirus and proliferation was examined in a 
proliferation curve by counting cells; 
and mature miR-21 was measured by Northern blot. Quantification of miR
ratio was detected with Image Quant 5.0
for C: Spry1 and D: Spry2 
Spry2 was done with Image Q
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As seen in Figure 24 mature miR
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primiR 21 virus up to 2.8 fold higher compared to cells which were infected with a 
control virus, which shows that overexpression of miR
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MiR-21 expression was determined by Northern blot. Equa
U6 Northern blot; B: Quantification of miR
software. MiR-21 expression was normalized to U6 and the expression of the control 
cells. 
 
  
-21 levels increase when infected wit
 21. Dependent on the concentration of the virus miR
-21 in U373 work
with newly synthesized pAdlox primiR 
l loading was controlled by 
-21 was done with Image Quant 5.0
76 
h the 
-
lox 
s. 
 
21 virus A: 
 
77 
 
4.5.3 Comparison of different constructs for miR-21 inhibition 
4.5.3.1 Inhibition of miR-21 by pAdlox sponge eraser 21 
The influence of pAdlox sponge eraser 21 on miR-21 levels was tested in the cell 
lines U373 and A427. Therefore cells were infected with 3 different concentrations of 
the adenovirus, 48 hours after infection cells were harvest and RNA was isolated. For 
detection of miR-21 and U6, which was used for the control of equal loading, 
Northern blot was performed (Figure 25A). 
To investigate if miR-21 function was inhibited by expressing the sponge eraser, 
Spry1 and Spry2 protein levels, both verified targets of miR-21, were determined by 
Western blot. Cells were infected with 3 different concentrations of the virus and were 
harvest 48 hours post infection. Total proteins were isolated, page gel and Western 
blot were performed. Membranes were incubated in Spry1 and Spry2 primary 
antibody, followed by an incubation in total Erk or β Actin antibody to verify equal 
loading (Figure 25C+D upper panel). 
In U373, inhibition of miR-21 expression is shown to be significant, when cells were 
infected with the middle (p<0.001) or the high concentration (p=0.0043) of the virus. 
Interestingly the decrease in miR-21 level is improved when cells were infected with 
the middle concentration of the virus (mean±STD= 0.4±0.1) compared to the 
decrease in cells which were infected with higher amounts (mean±STD= 0.7±0.2). 
Cell infected with low levels of the sponge eraser 21 virus do not show any effect on 
miR-21 expression (mean±STD= 1.0±0.4) (Figure 25B). 
In contrast to the results of the Northern blot, no significant difference on the protein 
level of Spry1 and Spry2 can be found.  
Spry1 level shows a high standard deviation when cells were infected with low 
(mean±STD=1.08±0.81) and middle concentration (mean±STD=1.02±0.88) of the 
virus. Only cells infected with the highest level of pAdlox sponge eraser 21 show 
increased Spry1 level (mean±STD=1.67±0.33), but no statistical significance can be 
observed (p=0.096) (Figure 25C lower panel). 
Also quantification of Spry2/ total Erk ratio show high standard deviation, so that no 
increased of Spry2 levels can be observed (Figure 25D lower panel). 
 Figure 25: Influence of pAdlox sponge eraser
function in U373 A: A representative Northern blots of miR
Equal loading was determined by U6 loading control. 
blots after quantification of miR
levels were normalized to U6 and to the expression of miR
Significance was analyzed with t
p<0.001) Levels of C: Spry1 and 
eraser 21 were detected by Western blotting (upper panel). One representative of 2 
blots is shown. Quantification was carried out with Image Quant 5.0 program. 
Expression levels as ratio to β 
(lower panel). 
 21 infection on miR-21 expression and 
-21 expression is shown. 
B: Summary of the 3 Northern 
-21/ U6 using Image Quant 5.0 
-21 in 
-test in Graph Pad Prism (* p<0.05; ** p<
D: Spry2 of U373 after infection with pAdlox sponge 
Actin or total Erk were normalized to control cells 
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software. MiR-21 
control cells. 
0.01; *** 
79 
 
In A427 all 3 concentrations of the pAdlox sponge eraser 21 virus causes almost the 
same miR-21 levels compared to the control cells. 
Although in Western blot no increase of Spry1 and Spry2 can be found (Figure 26C+ 
D upper panel). Quantification of Spry1 levels show no big fluctuation between cells 
infected with a low, middle and high concentration of the virus (Figure 26C lower 
panel), while Spry2 levels are changed. Cells infected with low and high 
concentration show a trend of increased Spry2 expression (Figure 26D lower panel). 
Nonetheless we assumed that this construct does not work in this specific cell line. 
  
 Figure 26: Influence of pAdlox sponge eraser
function in A427 A: Northern blot of miR
determined by U6 loading control. 
5.0 software was used. MiR
miR-21 in cells infected with a control virus. Levels of 
after infection with pAdlox sponge eraser
(upper panel). Quantification w
Expression levels as ratio to β 
(lower panel). 
 21 infection on miR-21 expression and 
-21 expression is shown. Equal loading was 
B: For quantification of miR-21/ 
-21 levels were normalized to U6 and to the expression of 
C: Spry1 and 
 21 were detected by Western blotting 
as carried out with Image Quant 5.0 program. 
Actin or total Erk were normalized to control cells 
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4.5.3.2 Inhibition of miR-21 by pAdlox oligo eraser 21 
To examine if pAdlox oligo eraser 21 has the excepted influence on miR-21 
expression, the cell lines U373 were infected with 3 different ratios of the adenovirus. 
48 hours after infection cells were harvest and total protein and total RNA were 
isolated. For detection of miR-21 expression Northern blot was performed. Detection 
of U6 was used as loading control (Figure 27A). 
In U373 cell line no difference in miR-21 expression of cells infected with the pAdlox 
oligo eraser 21 virus compared to control cells can be observed. Quantification of 
miR-21 levels of control cells leads to a mean of 1.4. Cells infected with the lowest 
level of the virus show on average a slightly increased expression of miR-21 
(mean±STD= 1.73±0.02), while infection with the middle lead to no decrease 
(mean±STD= 1.29±0.37). Cells infected with the highest level show nearly the same 
miR-21 expression like the control cells (mean±STD=1.09±0.45). MiR-21 levels are 
not influenced by this eraser construct (Figure 27B). 
Since it is possible that the construct has only an influence on the protein level, 
Western blot for Spry1 and Spry2 was performed, too. Equal loading of samples were 
controlled with incubation of the membrane in β Actin or total Erk antibody (Figure 
27C+D upper panel). 
In U373 cells no difference between infected cells and control cells at the protein 
level of Spry1 and Spry2 can be observed. Spry1 levels detected from cells infected 
with pAdlox oligo eraser 21 show high standard deviation. On average cells infected 
with the middle (mean±STD= 1.60±1.04) and the highest concentration (mean±STD= 
1.44±0.93) of the virus show increased Spry1 levels, but due to the huge standard 
deviation no statistical significance can be observed (Figure 27C upper panel). 
Expression of Spry2 cells infected with the low and the high level of the virus is nearly 
the same. Only middle concentration had an effect and leads on average to an 
increase of Spry2 expression (mean±STD= 2.03±0.42), but no statistical significance 
can be observed (p=0.075) (Figure 27D upper panel). 
 
 Figure 27: Influence of pAdlox oligo eraser
function in U373 A: A representative Northern blots of miR
Equal loading was determined by U6 loading control. 
blots after quantification of miR
levels were normalized to U6 and to the expression of miR
control virus. Levels of C: 
oligo eraser 21 were detected by W
of 2 blots is shown. Quantification was carried out with Image Quant 5.0 program. 
Expression levels as ratio to β 
(lower panel). 
 21 infection on miR-21 expression and 
-21 expression is shown. 
B: Summary of the 3 Northern 
-21/ U6 using Image Quant 5.0 
-21 in cells infected with a 
Spry1 and D: Spry2 of U373 after infection with pAd
estern blotting (upper panel). One representative 
Actin or total Erk were normalized to control cells 
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To examine if pAdlox oligo eraser 21 has the excepted influence on miR-21 
expression, the cell line A427 were infected with 2 different ratios of the adenovirus. 
48 hours after infection cells were harvest and total protein and total RNA were 
isolated. MiR-21 expression was detected by Northern blot. For loading control, 
Northern blot of U6 was used (Figure 28A). Additionally Western blots for Spry1 and 
Spry2 were performed, to examine the influence of the construct on protein level 
(Figure 28C+D upper panel). 
In A427 no difference between infected cells and control cells at the miR-21 can be 
observed (Figure 28B). 
Spry1 and Spry2 levels are increased in cells infected with low ratio of the virus, while 
at the high concentration expression of these proteins decreases in comparison to 
the expression in control cells (Figure 28C+D lower panel).  
  
 Figure 28: Influence of pAdlox oligo e
function in A427 A: Northern blot of miR
determined by U6 loading control. 
5.0 software was used. MiR
miR-21 in cells infected with a control virus. Levels of 
after infection with pAdlox oligo eraser 21 were detected by Western blotting (upper 
panel). Quantification was carried out with Ima
levels as ratio to β Actin were normalized to control cells (lower panel).
 
raser 21 infection on miR-21 expression and 
-21 expression is shown. Equal loading was 
B: For quantification of miR-21/ 
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 4.5.3.3 Inhibition of miR
Figure 29: Influence of pAdlox simiR 21 infection on miR
in U373 and A427 A: A representative Northern blot of miR
shown. Equal loading was determined by U6 loading control. 
Northern blots of U373 after quantification of miR
program. MiR-21 levels were norm
control cells. C: Northern blot of miR
was determined by U6 loading control. 
Quant 5.0 software was used. MiR
expression of miR-21 in cells infected with a control virus.
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To examine if pAdlox simiR 21 virus will be successful in inhibition of miR-21 
expression, U373 and A427 cells were infected with 3 different concentrations. 48 
hours post infection cells were harvest and RNA was isolated and miR-21 levels were 
detected by Northern blotting. Equal loading of the samples was verified by 
hybridization with U6 (Figure 29A+C).  
In both cell lines no decrease of miR-21 expression can be observed. In U373 no 
difference in the miR-21 levels to the expression in control cells can be found, no 
matter which infection ratio was used (Figure 29B). 
In A427 inhibition of miR-21 by pAdlox simiR 21 does not works, too. In contrast to 
the supposed results, miR-21 is slightly increased after infection with pAdlox simiR 21 
compared to the control cells (Figure 29D). 
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5 DISCUSSION 
MiR-21 is shown to be upregulated in lung tumor compared to normal tissue (38) 
(39), while Spry2 is downregulated in NSCLC (74). In this study endogenous levels of 
miR-21 from 14 NSCLC-derived cell lines were analyzed and the expression was 
compared to normal fibroblast cells (WI-38). In contrast to the results observed from 
tissue (38) (39), no NSCLC-derived cell line shows a more than 2-fold increase of 
miR-21 expression by comparison with the levels in WI-38 and there were also cell 
lines which expressed lower levels of miR-21 than normal lung fibroblasts. Conform 
with these results, it is demonstrated, that miR-21 expression in colon cancer-derived 
cell lines fails to be increased (85) or only shows rare changes (86), while in 
colorectal tumor tissue levels are usually elevated (33) (34). Overexpression of miR-
21 in cancer derived-cell lines which were cultured under standardized conditions is 
only observed in glioblastoma (30). By comparison of the proliferation rate of the cell 
lines, we cannot show a significant difference between miR-21 levels of slow and fast 
cell lines. 
 
Cell lines, which harbor a K-Ras mutation, have on average higher levels of miR-21 
than cells with the wt of this gene. All cell lines with a K-Ras mutation are 
adenocarcinomas, which is not surprising because this mutation was mostly found in 
adenocarcinomas and is very uncommon in squamous cell carcinomas (87). In 
literature it is shown in tissue, that adenocarcinomas have on average a higher miR-
21 expression than tumors staged as squamous cell carcinoma (88). In this study 
miR-21 levels in cell lines harboring an activating mutation in K-Ras and EGFR gene 
show no significant difference compared with cell lines with the wt gene. Literature 
shows that EGFR (89) and K-Ras mutations (90) (91) influence the expression of 
miR-21. This is not in contrast to our findings, because in these studies the influence 
of changed pathways was analyzed in tissue. Seike et al. show that the level of 
phosphorylated EGFR correlates with the expression of miR-21 in tissue of never 
smokers (89). Frezetti et al. and Hatley et al. analyze the influence of oncogenic Ras 
on miR-21 levels by comparing tissue from adenocarcinomas, which were activated 
by Ras expression with normal tissue (90) (91). Our data show that overexpression of 
ongenic K-, H- and N-Ras via adenoviral system in WI-38, does not lead to an 
increase in miR-21 levels. 
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These results indicate that miR-21 in NSCLC-derived cell lines is not increased by 
intrinsic alteration of cancer, but maybe by external factors. As a consequence of this 
study, further experiments will be necessary to investigate why miR-21 is highly 
overexpressed in tumor tissue while no upregulation in NSCLC-derived cell lines can 
be found.   
 
The investigated miR-21 substrates show no correlation with miR-21 expression. This 
can be due to the fact, that no huge difference in miR-21 levels between the cell lines 
can be found. Additionally proteins are not only regulated by one factor and it is 
possible that other regulatory signaling have more influence on protein expression 
than miR-21. In the case of Spry2 there are several possibilities how it can be 
regulated, like ubiquitination through c-Cbl (64) or by the influence of PTEN (48). 
Additionally Spry1 and Spry2 are regulated by a negative feedback loop in MAPK 
pathway (56). PDCD4 is not only regulated by miR-21, but also for example 
phosphorylation by S6K1 and/ or Akt influence its stability (92) (93). PTEN is known 
to be regulated by various molecular mechanisms at mRNA and protein level (94). 
Due to this knowledge, miR-21 is only one of many ways to influence regulation of 
PDCD4, PTEN, Spry1 and Spry2. 
 
Spry1 and 2 are known to be targets of miR-21 and are negatively regulated by this 
miRNA (46) (47). Overexpression of human Spry1 in WI-38 fails to change miR-21 
expression, while miR-21 is decreased when Spry2 is highly overexpressed. Lower 
concentrations of Spry2 do not show an effect on miR-21 levels. MiR-21 expression 
is known to be regulated via a negative feedback-loop involving PDCD4 and AP-1. 
PDCD4 was also found to be a negative AP-1 regulator. Downregulation of PDCD4 
by miR-21 is necessary for activation of AP-1 in response to Ras (43). According to 
the results of our study, Spry1 is no regulator of miR-21 expression, while high levels 
of Spry2 seem to have an influence on miR-21 levels by a positive and not as 
supposed by a negative feedback loop. This result must be confirmed by further 
experiments, where adequate levels of Spry2 are expressed.  
 
Due to the fact that miRNAs are involved in nearly every cellular process, like cell 
differentiation (95), proliferation and apoptosis (96), a lot of research of miRNAs as 
anticancer therapeutic was done. Modulation of miRNA by overexpressing or 
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inhibiting them, are important tools for therapeutic as well for more detailed 
understanding of the influence of miRNAs on proliferation and migration. Chan et al. 
show that miRNA-21 knock down leads to an activation of caspases and induces 
apoptosis in glioblastoma cells (30), while overexpression of miR-21 in myeloma cells 
inhibits programmed cell death (42). MiR-21 was also found to promote cell invasion 
and metastasis in colorectal cancer (45) and inhibition of miR-21 leads to decreased 
cell growth in vivo and in vitro (97). 
 
For the overexpression of miR-21 there are three strategies: MiR-21 can be 
overexpressed as its mature form or as one of its precursors (pre- or primiR 21) (24). 
For this study, it was decided to overexpress primiR 21 constructs. Overexpression of 
miR-21 works in our study, even when we can only observe a 2.8 fold increase. In 
literature there is a study, which uses the expression of a part of the primiR 21 
precursor loop, including the sequence of premiR 21 and variable flanking sites. Yue 
et al. utilize primiR 21 constructs with 400 bp upstream and 135 bp downstream or 
160 bp upstream and 35 bp downstream flanking sequence and after transfection in 
293FT cells mature miR-21 and primiR 21 levels were detected. They explored, that 
if premiR 21 has a short flanking sequence the expression of miR-21 is more efficient 
than it has a long flanking sequence (98).The reason why precursors are preferred to 
be used for overexpression is, that during miRNA biogenesis diverse factors are 
active which are important for the function of mature miRNA. For example 
microprocessors, which includes Drosha and DGCR8 and which are active at the first 
cleavage step of processing of primiR to premiR. They are integrated in signaling 
events from different pathways which results in changes of miRNA expression. There 
are also RNA-binding proteins which directly bind to the primiR and are so involved in 
the expression of miRNAs (99). 
 
In our study for inhibition of miR-21 three different constructs were used: The first 
strategy are antisense oligonucleotides (pAdlox oligo eraser 21 under control of U6 
promoter, a RNA polymerase III promoter), the second a miRNA sponge (pAdlox 
sponge eraser 21 under control of a CMV promoter, a RNA polymerase II promoter) 
and the third a shRNA against primiR 21 (pAdlox simiR 21). All constructs are 
expressed via the adenoviral system in glioblastoma cell line (U373) and in NSCLC-
derived cell line (A427) and the efficiency of the constructs in both cell lines was 
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compared. No modulation of miR-21 in A427 can be found, with none of the three 
erasers. In U373 cells the sponge construct leads to a significant decrease of miR-21 
levels.  
 
Antisense oligonucleotides were the first tool to modulate miRNA expression and 
their functionality was proven in several studies. Studies demonstrated that 2’-O-
methyl oligonucleotides silence the activity of miRNAs in vivo as well as in vitro (100) 
(101). LNA-modified oligonucleotides are able to inhibit endogenous miRNA levels in 
Drosophila cells as well as exogenous introduced miRNAs (102). Krützfeld et al. used 
so called “antagomiRs”, oligonucleotides with a phosphorothioate backbone and 
modification at the 3’end as well as 2’-O-methyl modification to inactivate miRNA 
functions in vivo (103). Modification leads to induced and increased efficiency of 
inhibition, but is maybe not necessary to inhibit miRNAs. In our study pAdlox oligo 
eraser-21 fails to inhibit miR-21 in both cell lines. Additionally Spry1 and Spry2, as 
examples for miR-21 substrates are unaffected, indicating that either we looked at 
the wrong substrates or this method does not work in our experiments.  
 
Usage of miRNA sponges, a new strategy to modulate miR-21 expression, shows 
several advantages compared to antisense oligonucleotides. Sponges are often 
associated with reporter genes like GFP or luciferase, so it is easy to select or screen 
for cells which express sponge (104). Furthermore, regulatory elements can be 
integrated in the promoter of the sponge, so that the constructs are drug inducible 
and tissue specific (104), while antisense oligonucleotides which are injected into 
mice, are not expressed constantly through tissue and mostly accumulate in the liver 
(103). Sponges are shown by Ebert et al. to inhibit all tested miRNAs (miR-15, miR-
18, miR-20, miR-21 and miR-30) more effective in comparison to antisense 
oligonucleotides which were transfected in the same concentration in 293T cells (26). 
The sponge construct, used in our study works only in glioblastoma cell line U373, 
cells which have high endogenous miR-21 expression. The experiment in A427 fails, 
maybe because this cell line expresses only basal levels of miR-21 and for this 
reason sponge eraser cannot work. 
As mentioned before sponges have multiple binding sites for their target miRNA. 
These sites can show perfect basepairing or some mismatches, so called buggle 
sites at position 9-12. The sponges with buggle sites are demonstrated in several 
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studies to be more effective than sponges with perfectly match (26) (105) (106). 
Kluiver et al. performed GFP competition assays which show that miR-19 sponges 
with bugled binding sites inhibit the target miRNA more effective compared to 
sponges without mismatch (107). This can be caused by a more stable interaction 
with the target miRNA or by the degradation of sponge as a result of the cleavage 
activity of AGO2 (108) (109). Nevertheless there are examples in literature which 
show that sponges with total complementary work too (47) (110) (111). 
Additional to the factors described before, the number of binding sites is important for 
the function of a sponge eraser. More binding sites can maximize the inhibitory 
function of the eraser and can increase the degradation of the sponge transcript 
(112). But there are also limited effects as shown from Kluvier et al. (107). MiR-19 
sponges with 6 repeating binding sites in murine cells inhibit miRNA at the same 
grade as a sponge with more repeats. This indicates that there is a sufficient level of 
sponges for maximal inhibition, which can be dependent on the level of endogenous 
miRNA and their binding activity to sponges. We detected also a dosage effect in our 
study: the maximum decrease of miR-21 due to the inhibitory effect of the sponge 
construct can be found in the middle concentration of the virus. When cells get 
infected with the highest amounts of virus, miR-21 expression is increased compared 
to levels at the middle expression but still significantly decreased in comparison with 
control cells.  
We used sponge constructs with a total complementary and two binding sites in this 
study. For further experiments, to improve the function of pAdlox sponge eraser 21 it 
will be necessary to construct a new eraser construct, with more than two binding 
sites and sequences which shows not totally complementary to miR-21.  
 
With exception of the study from Sayed et al. who introduce miR-21 sponges via viral 
vectors into cells (47), all studies do not show decrease of the target miRNA, they 
only investigate the expression of reporter genes or of target genes of the miRNA of 
interest. Due to this fact, at the start of our experiments we cannot exclude, that 
sponge erasers only work at the protein level of cells. Therefore we performed, 
beside Northern blots to detect miR-21 levels, Western blots of Spry1 and Spry2, 
confirmed targets of miR-21. Interestingly we can observe a decrease in miR-21 
expression after infection of cells with pAdlox sponge eraser 21, but Spry1 and Spry2 
levels are unaffected. 
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Another strategy to inhibit miRNAs that we used is a RNAi method, so called siRNAs 
or shRNAs. SimiR includes the sequence of primiR of the target miRNA, so that they 
can work in the nucleus, where miRNA processing takes place. A long time period it 
was thought that RNAi methods are useless to inhibit miRNAs, due to the fact that 
siRNAs are mainly active in the cytoplasm. But since hairpin siRNA can be 
expressed, RNAi can be a successful strategy to modulate miRNA levels by influence 
the processing of the precursors to mature miRNA (25). In the experiments shown in 
this study, siRNA-21with the sequence we choose does not work. Possibly inhibition 
of miR-21 by RNAi tools which are active in the nucleus, does not work so far, but 
there is also the chance that another sequence can lead to inhibition of miR-21 
expression. 
 
Further investigations of the influence of modulation of miR-21 on proliferation will be 
helpful to understand the oncogenic action of this specific oncomiR and to evaluate 
the potential of miR-21 as an anticancer- therapeutic.  
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6 ABBREVIATIONS 
AGO Argonaut protein 
Amp Ampicilin 
AP-1 Activator protein1 
APS Ammoniumpersulfate 
ATP Adenosin-5‘-triphosphate 
Bcl-2 B-cell lymphoma 2 
BDNF Brain-Derived Neurotrophic Factor 
bp basepair(s) 
c-Cbl Casitas B-lineage-lymphoma 
CFP cyan fluorescent protein 
CMV cytomegalovirus 
Dcp1 mRNA-decapping enzyme 1 
ddH2O double-distilled water 
DepC- ddH2O Diethylpyrocarbonate double-distilled water 
DGCR8 DiGeorge syndrome critical region gene 8 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
dNTPs deoxy-nucleotide tri-phosphates 
EGF/EGFR Epidermal Growth Factor/ Epidermal Growth Factor 
Receptor 
Erk extracellular-signal-regulated kinase 
FCS Fetal calf serum 
FGF Fibroblast Growth Factor 
FHIT Fragile histidine triade 
GDNF Glial cell line-Derived Neurotrophic Factor 
GFP green fluorescent protein 
Grb2 Growth factor receptor-bound protein 2 
GTP Guanosine-5'-triphosphate 
HGF Hepatocyte Growth Factor 
HRP horseradish peroxidase 
Hrs Hepatocyte growth factor-regulated tyrosine substrate 
Igf  Insulin-like growth factor 
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LB Lysogeny Broth 
MAPK Mitogen-activated protein kinase 
MCS multiple cloning sites 
min minute(s) 
miR-21 microRNA-21 
miRISCs miRNA-induced silencing complexes 
miR-mask miR-masking antisense oligonucleotides technology 
miRNA microRNA 
MOPS N-morpholino propanesulfonic acid 
mRNA messanger RNA 
NGF Nerve Growth Factor 
NSCLC Non small cell lung cancer 
nt nucleotides 
o/n over night 
OD Optical density 
PAGE polyacrylamide gel electrophorese 
PBS Phosphate buffered saline 
PCI Phenol-Chloroform-Isoamylalkohol 
PCR Polymerase chain reaction 
PDCD4 Programmed Cell Death4 
PDGF Platelet-Derived Growth Factor 
PLC Phospholipase C 
PNK Polynucleotidkinase 
premiR precursor miRNA 
primiR primary transcript miRNA 
PTB phosphotyrosine-binding domain 
PTEN Phosphatase and tensin homolog 
Rb Retinoblastoma 
RBD Raf-1 binding domain 
RNAi RNA interference 
RNP Ribonucleoprotein complexes  
rpm rounds per minute 
RTK Receptor tyrosine kinase 
SAP Shrimp Alkaline Phosphatase 
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SCF Stem cell factor 
SCLC Small cell lung cancer 
SDS Sodium dodecylsulfate 
sec second(s)  
SH2 Src homology 2 
siRNA small interfering RNA 
SN Supernatant 
Sos son of sevenless 
Spry Sprouty proteins 
STAT3 Signal transducers and activator of transcription3 
STETL Sucrose –Triton–EDTA –Tris–HCl–Lysozyme 
T/E Trypsin/ EDTA 
TEMED Tetramethylethylenediamine 
TGF-β1 Transforming growth factor-β1 
TMEM49 Transmembrane protein 49  
TRBP human immunodeficiency virus transactivating 
response RNA-binding protein 
UTR untranslated region 
VEGF vascular endothelial growth factor 
wt wildetype 
Xrn 1 5'-3' exoribonuclease 1 
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10  APPENDIX 
10.1 Primer sequences 
U6 promotor 
NAME SEQUENCE 5’- 3’ 
U6 promotor sense AGCTCTCGAGCGGTGTTTCGTCCTTT 
U6 promotor antisense AGCTGTCGACAAGGTCGGGCAGGAAGAGGG 
 
simiR 21 
NAME SEQUENCE 5’- 3’ 
simiR 21 sense 
GATCAAAAAAAAGTTCAGCTATGGTAAGAGCCTTGGTTTAT
CAAGCTTCATAAACCAAGGCTCTTACCATAGCTGAACC 
simiR 21 antisense 
TCGAGTTCAGCTATGGTAAGAGCCTTGGTTTATGAAGCTTG
ATAAACCAAGGCTCTTACCATAGCTGAACTTTTTTTTG 
 
10.2 Probes 
NAME SEQUENCE 3‘-5‘ 
miR-21 TCAACATCAGTCTGATAAGCTA 
U6 (probe for HomosapiensU6smallnuclear2 
RNA (RNU6-2)): 
CACGAATTTGCGTGTCATCCTT 
5srRNA ATTCCCAGGCGGTCTCCCATCC 
 
  
 10.3 Vector maps
 
 
pAdlox primiR 21
  
 
pAdlox oligo eraser
 
  
pAd oligo eraser21
3864 bps
500
1500
2000
2500
3000
3500
SfiI
ORI
U6 promotor
eraser miR-21
Amp resistance
 
 
 
pAdlox sponge eraser
 
 
 21 
 
pAdlox simiR 
 
 
 
pAd sponge eraser21
5925 bps
3000
4000
5000
XhoIBglII
SfiI
SfiI
ORI
CMV Promotor
tandem eraser
Amp resistance
1000
NdeI
XhoI
EcoRI
BglII
SfiI
pAd simiR-21
3646 bps
1500
2000
2500
3000
3500
SfiI
ORI
Amp resistance
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 21 
 
21 
 
1000
2000
XhoI
NdeI
luciferase
500
1000
XhoI
HindIII
SfiI
U6 promotor
siprimiR 21
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